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Abstract 
The ability of cell-penetrating peptides (CPPs) to translocate a variety of covalently or non-
covalently linked cargoes, particularly therapeutics and imaging agents, across the plasma 
membrane of living cells renders them of broad interest in the medical field as well as in 
biotechnological development. Thus, the use of CPPs, e.g. in therapeutics, increases the 
necessity of understanding their mechanism of action, a subject still under debate. 
For the first step of peptide internalization, the interaction between the positively charged 
amino acid side chains within the peptide sequence and the anionic constituents of the 
membrane bilayer is assumed. However, owing to the complexity of biological plasma 
membranes, studying the mode of action of CPPs on a molecular level is very difficult. With 
this in mind, model membrane systems, especially large and giant unilamellar vesicles and 
giant plasma membranes vesicles derived from live cells plasma membranes, were 
prepared and several techniques were established in order to monitor the initial step of cell 
entry – binding to and translocation through the cell membrane as well as identification of 
key components of the plasma membrane required for efficient uptake. 
The first chapter focuses on the membrane interactions and perturbation mechanism of two 
structural modified variants of the well-described CPP sC18, a cyclized and a dimeric 
branched version, with artificial model membranes. Fluorescence analysis demonstrated 
the importance of negatively charged lipids for an efficient uptake of Arg-rich CPPs, 
supporting the assumption that electrostatic interactions are required for the initial stage of 
cell entry. In case of dimeric variants, the strong affinity was further accompanied by intense 
membrane destabilizing effects, presumably responsible for their lytic behavior as 
anticancer peptide. Moreover, the cyclization of the peptide backbone turned out to be a 
promising strategy as well to improve their cell-penetrating capability. Using CD 
spectroscopy, structural arrangements when in contact with neutral and anionic vesicles 
further revealed that a certain flexibility and thus the static arrangement of the guanidinium 
groups within the cycle seem to positively affect peptide-membrane interaction. In summary, 
these evidences suggest that the internalization of the peptide variants depends highly on 
the membrane composition of the target cell. 
In the second chapter, the focus lay on the design and characterization of novel peptide 
conjugates, composing of a wound healing promoting peptide and sC18 as cell penetrating 
peptide, with the final goal to further enhance the wound healing activity. Besides, the new 
conjugate Tylotoin-sC18* exhibited further promising antimicrobial activity and moreover a 
certain selectivity towards cancer cells, suggesting that Tylotoin-sC18* is a good candidate 
for further studies and the possible development as a therapeutic agent for infected wounds.  
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Zusammenfassung  
Die Fähigkeit zellpenetrierender Peptide (cell-penetrating peptides, CPPs) die 
Plasmamembran lebender Zellen passieren zu können und dabei kovalent und nicht-
kovalent gebundene Moleküle, insbesondere therapeutisch aktive Wirkstoffe und 
Farbstoffe, zu transportieren, macht sie sowohl für die Medizin als auch für den 
Biotechnologiesektor besonders interessant. Für eine erfolgreiche therapeutische 
Anwendung zellpenetrierender Peptide ist die Erforschung derer genauen 
Wirkmechanismen essentiell. Als erster Schritt der Internalisierung wird dabei 
weithingehend die Interaktion der positiv geladenen Aminosäuren innerhalb der 
Peptidsequenz mit den negativ geladenen Komponenten der Membrandoppelschicht 
angenommen. Eine besondere Herausforderung der Forschung stellt jedoch die 
Komplexität biologischer Plasmamembranen dar, weswegen sich die Aufklärung der 
Wirkmechanismen zellpenetrierender Peptide auf molekularer Ebene als besonders 
schwierig erweist.  
Vor diesem Hintergrund wurde sich für den Einsatz artifizieller Modell-Membran-Systeme, 
insbesondere unilamellare Liposomen (large and giant unilamellar vesicles, LUVs and 
GUVs) und Membranvesikel (ginat plasma membrane vesicles, GPMVs), die von lebenden 
Zellmembranen abstammen, entschieden. Darauf basierend wurden in dieser Arbeit 
verschiedene Techniken etabliert, welche die Untersuchung des ersten Schrittes der 
Internalisierung in die Zelle – die Anbindung, sowie die Translokation durch die 
Zellmembran – ermöglichen sollten. Weiterhin sollten die Schlüsselkomponenten, welche 
zur effizienten Aufnahme beitragen, identifiziert werden. 
Das erste Kapitel widmet sich den Interaktions- und Destabilisierungsprozessen zweier 
strukturell modifizierten Varianten des bereits gut untersuchten zellpenetrierenden Peptides 
sC18, einer zyklisierten und einer verzweigten Version, unter Verwendung von artifiziellen 
Modellmembranen. Dabei stellten Fluoreszenzanalysen die Wichtigkeit negativ geladener 
Lipide für die effiziente Aufnahme Arg-reicher Peptide heraus. Dies unterstützt die 
Vermutung, dass elektrostatische Interaktionen in der ersten Phase der Zellpenetration eine 
zentrale Rolle spielen. Im Fall der verzweigten Varianten zeigte sich, dass deren starke 
Affinität von intensiven Destabilisierungseffekten der Membran begleitet wurde. Diese 
könnten für deren lytisches Verhalten als Zytostatika-Peptid verantwortlich sein. Weiterhin 
erwies sich die Zyklisierung des Peptid-Rückgrats als vielversprechende Strategie zur 
Verbesserung der Zellinternalisierung. CD-spektroskopische Analysen mit neutral und 
negativ geladenen Vesikeln zeigten, dass eine gewisse Flexibilität und damit die Anordnung 
der Guanidiniumgruppen innerhalb des Zyklus die Peptid-Membran-Interaktion positiv 
beeinflussen können. Zusammengefasst lassen die Ergebnisse darauf schließen, dass die 
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Internalisierung der Peptid-Varianten stark von der Membranzusammensetzung der 
Zielzelle abhängig ist, wodurch eine gewisse Selektivität vermutet wird. 
Im zweiten Kapitel lag der Fokus auf dem Design und der Charakterisierung eines neuen 
Peptid-Konjugats, welches sich aus dem wundheilungsfördernden Peptid Tylotoin und dem 
zellpenetrierenden Peptid sC18 zusammensetzt, mit dem Ziel den Wundheilungsprozess 
noch weiter zu beschleunigen. Das neue Konjugat Tylotoin-sC18* zeigte darüber hinaus 
eine vielversprechende antimikrobielle Wirkung und eine gewisse Selektivität gegenüber 
einer getesteten Krebszelllinie. Diese Eigenschaften machen Tylotoin-sC18* zu einem 
aussichtsreichen Kandidaten für weitere Studien, um eine neue Klasse von therapeutischen 
Wirkstoffen zur Behandlung infizierter Wunden zu entwickeln. 
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1. Introduction 
1.1 Biological and model membranes 
1.1.1 Eukaryotic and bacterial membranes 
Biological membranes play a crucial role in the cellular protection against the surrounding 
environment as well as in the control and the transport of nutrients. Particularly, cellular 
membranes are only permeable for compounds within a narrow range of size, net charge 
and polarity. Thereby, the membrane provides an efficient way for a cell to prevent 
uncontrolled influx or efflux of solutes and compounds, which could otherwise be harmful. 
[5]  
In 1925, Gorter et al. first suggested the concept that biological membranes are composed 
of two opposite layers of lipids [65]. Almost 50 years later, Singer et al. proposed the 
advanced fluid mosaic model, in which the biological membrane is considered as a two-
dimensional liquid where lipids and proteins diffuse more or less unhindered within the plane 
of the membrane [170].  
Since then, many developments were brought to this model in terms of the membrane 
composition and molecular organization, e.g. the discovery of lateral microdomain 
structures [167], revealing the complex nature of the cell membrane structure (Figure 1) 
[137].  
 
Figure 1. A schematic representation of the plasma membrane. (from Mariana Ruiz, 2007) 
In general, the plasma membrane is composed of three categories of membrane lipids 
according to their chemical structure, namely glycerol-based lipids, ceramide-based 
sphingolipids and cholesterol (Figure 2) [137].  
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Figure 2. Schematic illustration of the three main membrane lipids. Phospholipids (A) Glycolipid (B) and Cholesterol (C). 
(adapted from Watson, H., 2015 [197]) 
The glycerol-based lipids or phospholipids are the most abundant membrane lipids 
consisting of two fatty acid chains linked to glycerol and a phosphate group [197]. They are 
further classified into various subgroups based on their hydrophilic head groups which are 
then attached to the phosphate group [137]. The four major glycerol phospholipids are 
phosphatidylcholine (DOPC), phosphatidylethanolamine (DOPE), phosphatidylserine 
(DOPS) and phosphatidylinositol (PI) [204].  
Sphingolipids, another important group of membrane lipids, are composed of a sphingosine, 
instead of the glycerol backbone, which is attached to a long unsaturated hydrocarbon chain 
[5]. Moreover, sphingomyelin, which is the major sphingolipid in mammalian cells, is 
believed to be involved in the formation of lateral microdomains, so called lipid rafts [26]. In 
addition, cholesterol is also enriched in these microdomains of tightly packed domains [49] 
as result of its favorable interaction with the glycosphingolipids [159]. Subsequently, 
cholesterols hydrophilic carboxyl group interacts with the hydrophilic head groups of 
glycosphingolipids and the bulky hydrocarbon rings interact with the hydrophobic acyl 
chains of membrane lipids [137].  
The lipid compositions can be very different in various types of membranes, organisms and 
also between the two leaflets of the lipid bilayer [5, 60, 107]. Thus, several lipid species are 
distributed differentially in the two monolayers of biological membranes, resulting in 
asymmetric lipid distribution [107]. In mammalian cells, the outer leaflet of the plasma 
membrane contains predominantly phosphatidylcholine and sphingomyelin, whereas lipids 
with neutral or negatively charged head groups (e.g., phosphatidylethanolamine, 
phosphatidylserine, and phosphatidylinositol) are preferentially located in the inner leaflet 
[197]. However, cholesterol is present in both layers [203]. Furthermore, several studies 
revealed that the cell membrane composition changes in cancer cells, which is indicated by 
the overexpression of certain types of proteoglycans and the enrichment of negatively 
charged lipids, more precisely phosphatidylserine, in the outer leaflet [85, 120, 193]. Thus, 
phosphatidylserine is no longer restricted to the cytosolic leaflet of the plasma membrane 
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and is translocated to the outer leaflet by the action of an enzyme called scramblase [118, 
197]. Therefore, the membrane of cancer cells become more anionic than those of healthy 
cells.  
Moreover, the cell membranes of bacteria (gram-positive and gram-negative) differ in their 
composition significantly from mammalian cell membranes [60]. In particular, one of the 
major differences between bacterial and eukaryotic cell membranes is the presence of a 
large amount of cholesterol in eukaryotic cell membranes, while in bacterial cells, 
cholesterol is completely missing (Figure 3A) [23]. In addition, the membranes of bacteria 
are rich in negatively charged lipids, like phosphatidylglycerol and cardiolipin. 
Phosphatidylethanolamine is the most common neutral phospholipid in bacterial cell 
membranes (Figure 3A) [60, 63].  
 
Figure 3. Bacterial versus mammalian membranes. Schematic representation of the key features of the bacterial and 
mammalian cell membrane compositions (A). The membrane structure of gram-positive and gram-negative bacteria (B). ((A) 
adapted and modified from Brender et al., 2012 [23]; (B) adapted and modified from Chen and Bothun, 2014 [32]) 
Moreover, the outer membrane of gram-negative bacteria additionally comprises 
lipopolysaccharides as anionic components, whereas lipoteichoic acids are found in gram-
positive bacteria (Figure 3B) [60]. 
1.1.2 Vesicles as artificial model membrane system 
In general, model membrane systems are defined as artificial lipid bilayers in which the lipid 
compositions mimic the arrangement of those in biological cell membranes [137]. The 
interior of the spherical-shaped vesicles is characterized by aqueous solutions [164, 194]. 
Such liposomes are usually categorized, according to their size and lamellarity, into 
multilamellar vesicles (MLVs) and in small-, large- and giant unilamellar vesicles (SUVs, 
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LUVs and GUVs) [4]. Since MLVs are composed of multiple lipid bilayers, they are therefore 
not suitable and only rarely used as model membrane system [37].  
Large and giant unilamellar vesicles 
Large and giant unilamellar vesicles are the most studied and predominantly used model 
systems not only because of the more homogenous lipid distribution but also because of 
their suitable size. LUVs are characterized by diameters varying from 10 to 100 nm, while 
giant unilamellar vesicles have diameters above 10 µm and are therefore close to actual 
cell size [137].  
Furthermore, they can be relatively easy prepared by several methods. The most common 
method for the preparation of large unilamellar vesicles is illustrated in Figure 4. 
 
Figure 4. Formation of large unilamellar vesicles. Thin dried lipid films were hydrated and stacks of liquid crystalline 
bilayers become fluid and swell. Subsequently, hydrated lipid sheets self-close to form large, multilamellar vesicles (MLVs). 
To get LUVs, the size of the formed MLVs must be reduced by mechanical energy (extrusion). (modified after Lasic, A. D., 
1988 [103]) 
Classically, LUVs are prepared by dissolving lipids of interest in organic solvents like 
chloroform, followed by in vacuo evaporation to form a thin dried lipid film [137]. 
Subsequently, the dried lipid film is hydrated in aqueous buffer and MLVs will be formed. In 
order to obtain large unilamellar vesicles, the MLV suspension is then disrupted by several 
freeze-thaw cycles, which results in homogenous size distribution in the final suspension 
[137]. Finally, this suspension is subjected to extrusion through polycarbonate filters to 
produce large unilamellar vesicles with diameters up to 200 nm, depending on the pore size 
of the polycarbonate filter.  
GUVs are mostly prepared by electroformation [10], but this technique requires 
considerable technical effort. Whereas, the gentle hydration method, provided by Horger et 
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al., allows the preparation of giant unilamellar vesicles in a fast manner without the need of 
specialized equipment [76]. Going into detail, Horger and coworkers described the 
formation of giant unilamellar vesicles by hydration from a hybrid film of partially dried 
agarose and lipids [76]. In brief, a thin film of agarose will be prepared on a clean glass 
slide. Next, the lipid mixture, dissolved in chloroform, is applied on the dried agarose film 
resulting in the formation of a hybrid film of agarose and lipids. Finally, the last stage 
comprises the hydration of the hybrid film leading to the formation of GUVs within minutes. 
Giant plasma membrane vesicles obtained from live cells 
Giant plasma membrane vesicles are cell-derived vesicles and therefore provide a more 
natural system than large and giant unilamellar vesicles [162]. The attractiveness of GPMVs 
originates mostly from their complexity, since they maintain the lipid and protein diversity of 
cellular membranes, which they derived from [165]. GPMVs are released from cells upon 
chemical induction by either dithiothreitol (DTT) and formaldehyde (PFA) (Figure 5) or by 
N-ethylmaleimide (NEM) to avoid cross-linking-derived artifacts of lipids [14, 134, 165]. 
 
Figure 5. Principle of giant plasma membrane vesicle formation. (after Säälik et al., 2011 [156]) 
Moreover, GPMVs phase-segregate easily into liquid-ordered (Lo) and -disordered (Ld) lipid 
domains [156] They showed spherical shapes and varied in size up to 15 µm and are 
therefore distinctly smaller than GUVs. 
1.2 Cell-penetrating peptides 
The cellular plasma membrane constitutes an effective semi-permeable barrier that 
primarily protects living cells form the surrounding environment [111, 206]. At the same time, 
the cell membrane represents a barrier to the intracellular delivery of large hydrophilic 
molecules, e.g. for therapeutic applications [69]. Thus, the successful transport of such 
macromolecules to target specific cells and tissues is a major hurdle for administering 
bioactive molecules [52], which results in the necessity to find strategies allowing the 
efficient delivery of therapeutics across the membrane [145].  
In this regard, the ability of certain peptides, so called cell-penetrating peptides (CPPs), to 
cross the cellular membrane was simultaneously reported by Frankel and Pabo [57], and 
Green and Loewenstein [66] for the first time in the late 80s. Particularly, their research in 
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the field of AIDS revealed that the TAT peptide, derived from the human immunodeficiency 
virus (HIV), passes very efficiently through cell membranes of HeLa cells and promotes viral 
gene expression [57, 66].  
In general, cell-penetrating peptides are relatively short peptides containing less than 40 
amino acids, which are accompanied by an amphipathic or highly cationic character, usually 
rich in basic amino acids [36, 196]. Furthermore, CPPs are able to mediate the uptake of 
bioactive molecules into the cell, and thus transporting therapeutically active cargoes, 
including small molecules, plasmid DNA, siRNA, therapeutic proteins and imaging reagents 
[144, 145].  
Thus, the discovery of CPPs almost 30 years ago has paved the way for the development 
of cell delivery approaches and so, CPPs have gained considerable interest in clinical 
applications. 
1.2.1 Classification and uptake mechanisms 
Cell-penetrating peptides can be classified into different subgroups according either to their 
origin or to their physical-chemical characteristics [111, 210]. Based on their origin, three 
main classes of CPPs can be distinguished, including protein-derived peptides, chimeric 
peptides that are formed by the combination of two natural sequences, and finally synthetic 
peptides, which are rational designed sequences [16, 111]. Classical examples of each 
class are depicted in the following table. 
Table 1. Sequences and origins of well-studied CPPs. 
Peptide Origin Sequence Ref. 
Protein-derived peptides 
Tat(48-60) Protein Tat HIV-1 GRKKRRQRRRPPQ [192] 
Penetratin Antennapedia 
homeodomain 
RQIKIWFQNRRMKWKK [40] 
Chimeric peptides 
Transportan Galanin/ 
mastoparan 
GWTLNSAGYLLGKINLKALAALAKKIL [139] 
MAP de novo KLALKLALKALKAALKLA [132] 
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Synthetic peptides 
Oligoarginines Model peptide Rn [59, 
125] 
Pep-1 reverse 
transcriptase/T 
antigen 
KETWWETWWTEWSQPKKKRKV [42] 
 
According to their structure, CPPs can be categorized as cationic CPPs with a high positive 
net charge, hydrophobic CPPs consisting mostly of nonpolar amino acid residues and as 
amphipathic peptides comprising both polar and nonpolar regions [121, 122, 210]. The class 
of amphipathic CPPs can be further subdivided into primary and secondary amphipathic 
CPPs [210]. 
The first class, the cationic or nonamphipathic CPPs, are defined as rather short peptides, 
like Tat(48-60) or nona-arginine (R9), having a high content of positively charged amino 
acids (Arg or Lys) [151]. Further, it was shown that cationic peptides bind electrostatically 
to negatively charged components of the plasma membrane of cells, leading to efficient 
translocation [97]. Primary amphipathic CPPs, such as Transportan, typically consist of 
more than 20 amino acid residues and their primary structure includes hydrophilic and 
hydrophobic domains [155]. The uptake mechanism of these peptides is proposed to occur 
by the insertion into the surface of the cellular membrane followed by pore forming events 
(direct translocation, Figure 6) [210, 211]. The last group comprises the secondary 
amphipathic peptides, e.g. penetratin, containing normally less than 20 amino acids in their 
sequence [111]. They reveal their amphipathic properties only through a change in their 
secondary structure upon the interaction with the lipid membrane [111, 151, 210]. The 
membrane binding affinity of these peptides increases with the negatively charged lipid 
content of the membrane [210].  
Although, the exact mechanism used by CPPs to translocate across the cellular plasma 
membrane is not fully resolved, it is widely believed that the uptake mechanism varies for 
different classes of CPPs, and moreover, several mechanisms might even coexist 
depending on experimental conditions, such as the applied concentration, temperature, 
incubation time, the cell line used or the attached cargo [70, 111, 145, 151].  
However, the two proposed major translocation mechanisms of cell-penetrating peptides 
include the energy-dependent endocytotic pathway and the direct translocation via energy-
independent pathways [111, 206].  
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Figure 6. Scheme of different suggested uptake pathways for cell-penetrating peptides. (modified after Mickan et al., 
2014 [121]) 
Figure 6 summarizes the different uptake routes by which CPPs might penetrate the cell 
membrane. The endocytosis-mediated translocation mechanism, including clathrin-
mediated endocytosis and caveolae/lipid raft-mediated endocytosis as well as 
macropinocytosis, which provides the main pathway utilized by most CPPs, especially when 
peptides are attached to large cargo molecules [145, 206]. These four morphologically 
distinct pinocytotic pathways differ in the size of the coat (if any) and in the size of the 
detached vesicles [99]. However, endocytosis generally consists of two steps: the 
endocytotic entry which is followed by the endosomal release, whereby the latter step is 
crucial in order to avoid lysosomal degradation and moreover to allow the peptide/cargo to 
reach its extracellular target site [16].  
The uptake mechanism via direct translocation is most likely for primary amphipathic 
peptides at high CPP concentrations [111]. Three different energy-independent uptake 
pathways have been described: the inverted micelle model, the carpet model and the pore 
model, which is further divided into the toroidal pore and the barrel-stave model (Figure 6 
and 7) [155].  
 
Figure 7. Pore-forming models proposed for the cellular entry via direct translocation. (modified after Sanderson, J. M., 
2005 [159]) 
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In general, these models are mainly based on the electrostatic interaction of positively 
charged CPPs with negatively charged components of the cellular membrane (e.g. 
glycosaminoglycan and phospholipids), leading to the temporary or permanent 
destabilization of the lipid bilayer caused by the CPPs inserted in the membrane [155, 196]. 
More precisely, the inverted micelle mechanism causes local disorder of the lipid bilayer, 
which leads to the formation of such inverted hexagonal structures containing CPPs. As 
these micelles cross the membrane, they invert, which results in the destabilization of these 
micelles and finally, the release of the CPPs into the cytosol [145, 155, 186]. According to 
the carpet model, the peptide aligns parallel to the lipid membrane and when a threshold 
concentration is reached, transient pores can be formed that enable the translocation of the 
CPP into the cells [145, 159]. The mechanisms involved in the formation of “toroidal” and 
“barrel-stave” pores presumed the existence of a well-defined secondary structure of the 
CPP [186]. In the toroidal pore mechanism, the peptides insert into the lipid bilayer and 
bend the lipid monolayer into the interior, forming a hydrophilic pore in the cell membrane 
(Figure 7) [155]. In the barrel-stave model, the hydrophobic regions of the peptides interact 
with the hydrophobic core of the cell membrane, while the hydrophilic regions of the peptide 
face the lumen of the pore (Figure 7) [155, 159].  
In summary, the endocytotic pathway is supposed to be the dominant mechanism for the 
majority of CPPs, particularly when attached to large cargoes. However, it is essential to 
emphasize that the translocation pathway by which the cell-penetrating peptides enter into 
the cell depends on several parameters including (i) the nature and secondary structure of 
the CPP; (ii) its capability to interact with membrane components; (iii) the nature, type and 
concentration of the cargo; and (iv) the cell type and membrane composition [74]. 
1.2.2 Interactions of CPPs with membranes 
As already mentioned earlier, the first step of peptide internalization requires the 
electrostatically interaction between the cationic cell-penetrating peptide and the negatively 
charged constituents of the cell membrane [196]. Thus, when translocating through the 
cellular membrane, the first potential partners that CPPs will encounter at the cell surface 
are the negatively charged glycosaminoglycans and anionic phospholipids [36, 196]. 
The role of proteoglycans 
Proteoglycans are a heterogeneous group of proteins covalently attached with long, linear 
glycosaminoglycan (GAG) chains [6]. These chains are characterized by a high density of 
negatively charged sulfate and carboxylate groups [196]. Thus, proteoglycans are 
categorized according to the nature of the GAG chains [81]. Thereby, heparan sulfate (HS), 
chondroitin sulfate (CS) and dermatan sulfate (DS) are the most widespread GAGs in 
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proteoglycans [6]. As most CPPs contain positive charges, the peptide-GAG interaction is 
supposed to play a role in the internalization of peptides across the cell membrane, 
irrespective of the uptake mechanism [6, 140]. In this regard, taking into consideration that 
the most well-known CPPs are rich in Arg residues, the guanidium moieties of Arg could 
strongly interact with the sulfate and carboxylate groups of GAGs through bidentate 
hydrogen bonds (Figure 8A) [128, 196].  
The role of phospholipids 
Since the lipid composition of the plasma membrane, especially the anionic lipids, plays an 
essential role in the translocation pathway of CPPs, the negatively charged phospholipids 
of the cellular membrane represent the other main interaction partner of cell-penetrating 
peptides [6]. Despite lipids are not symmetrically distributed across the two leaflets of the 
cell membrane, anionic lipids are mainly found at the cytosolic site of the membrane and 
only a minor fraction is localized at the outer leaflet [36, 196]. Therefore, it is assumed that 
the peptides are able to recruit the anionic lipids in order to generate negatively charged 
nanodomains on the cell surface and thus allowing the critical internalization step [36, 196].  
The role of Arg residues 
Besides the evidence for the importance of anionic components in the cellular membrane 
and the cationic nature of CPPs, the type of the chemical hydrogen bond seems to be much 
more important [86].  
 
Figure 8. Interaction of arginine- and lysine rich peptides with negatively charged components of the plasma 
membrane. Favorable hydrogen bonding between guanidinium moieties of Arg-rich peptides and phosphate, sulfate and 
carboxylate groups of glycosaminoglycan (A). Differences in phosphate binding mechanism of Arg and Lys residues (B). 
(modified after Jobin et al., 2014 [86]) 
Several studies have shown that Arg-rich peptides efficiently penetrate the cells, while Lys-
rich CPPs do not, which is in accordance with the fact that the replacement of Arg by Lys 
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totally suppresses the cellular uptake of these CPPs [8, 86, 125]. In this context, Rothbard 
et al. revealed that Lys residues can only form monodentate interactions with the anionic 
cell surface which is not sufficient for the successful translocation of CPPs through the cell 
membrane, since Arg residues form bidentate hydrogen bonds (Figure 8B) [154].  
1.3 Skin and wound healing 
1.3.1 Skin as barrier 
The skin is the largest organ of the human body and is known to cover an area of up to 2 m2 
and its weight consists of more than 10 wt.% of the total weight of an adult body [89]. The 
primary function of the skin is to serve as a protective barrier against external mechanical, 
chemical, microbial and physical influences [41] and further helps to regulate the body 
temperature and permits the sensations of touch, heat, or pain [89]. The cellular architecture 
of the skin is depicted in Figure 9. 
 
Figure 9. Mammalian skin. The skin consists of the epidermis, the outermost layer of the skin and the dermis, the layer 
beneath the epidermis. The stratified structure of the epidermis is shown in the right panel. (adapted from Fuchs and 
Raghavan, 2002 [58]) 
The skin consists of two main tissue layers, the epidermis and the underlying connective 
tissue, which comprises the dermis and the hypodermis [5]. The epidermis is a multilayered 
epithelium mainly composed of keratinocytes [5]. The stratum corneum (SC), the outermost 
layer of the epidermis, consists of a 10 – 15 µm thick matrix of dead keratinocytes 
(corneocytes), which are surrounded by highly ordered lipid layers serving as cover. Thus, 
the SC provides the foremost barrier protecting our body from the influx of external materials 
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into the skin [22, 41]. The SC is underlaid by the viable epidermis (50 – 100 μm thick), which 
is responsible for the generation of the SC. The viable epidermis is composed of the 
granular, spinous and basal cell layer (Figure 9), whereby each layer is characterized by 
position, shape, morphology and state of the differentiation of keratinocytes [21, 22]. Directly 
adjacent to the epidermis lies the dermis, approximately 1 – 2 mm thick, providing the 
mechanical support for the skin. The dermis and also the hypodermis are thus highly 
supplied with blood vessels and nerves [5, 21, 22]. The hypodermis layer is composed of 
subcutaneous fat tissues providing thermal isolation and mechanical protection to the body 
[89]. In addition to the main tissues, sweat glands and hair follicles are spread throughout 
the skin [58]. 
1.3.2 Wound healing and peptides 
Since the skin serves as a protective barrier against the surrounding environment, any type 
of skin injury has to be mended in a rapid and efficient manner [119]. Wound healing is thus 
a critical process and starts normally immediately after the injury [169]. The cutaneous injury 
initiates a complex set of events comprising three overlapping phases: the inflammation, 
the proliferative process leading to tissue restoration and tissue remodeling (Figure 10) 
[109].  
 
Figure 10. The three stages involved in skin wound healing. (adapted from Kondo and Ishida, 2010 [96]) 
Cutaneous wound healing typically begins with the inflammation response, which is 
characterized by erythema, heat, swelling and pain, which are the results of capillary 
vasodilation and increased permeability [13]. Neutrophils and macrophages (inflammatory 
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cells) further infiltrate the wound site and trigger the process of wound healing [94]. The 
proliferative phase comprises the migration and proliferation of endothelial cells, fibroblasts 
and keratinocytes leading to re-epithelialization [109]. Approximately 4 days after injury, the 
dermal reconstitution begins at the wound site, which is characterized by the formation of 
granulation tissue including angiogenesis and collagen formation [96, 109]. The final stage 
of wound healing is the remodeling of the wound and the surrounding tissue by fibroblasts, 
which are responsible for the development of new epithelium and the final scar tissue 
formation. This stage of wound repair begins 2 – 3 weeks after injury and may last for one 
year or even longer depending on specific and individual factors such as the age of the 
patient, diseases and medication as well as the size, depth and cause of the wound [39, 
142, 191]. 
Efficient wound treatment remains one of the most prevalent healthcare issue, since 
thousands of patients suffered annually from different kinds of skin damage or burns by hot 
water, flames or accidents [33, 89]. Moreover, chronic wound patients, which suffer from 
diseases like type 2 diabetes, obesity, and wound infections account for increasing health 
care costs [163]. Therefore, much effort has been expended on wound care with an 
emphasis on new therapeutic approaches and the development of technologies for acute 
and chronic wound treatment [191].  
Until now, a plethora of studies exists concerning the therapeutic potential of antimicrobial 
peptides (AMPs) derived from multiple sources, e.g. humans or amphibians, as efficient 
modulators of wound healing [116]. In general, antimicrobial peptides, composed of 10 – 50 
amino acids, mostly exhibit an amphipathic character due to the prevalence of basic amino 
acid residues and a high content of hydrophobic amino acids [149]. AMPs, also known as 
host defense peptides, show a broad spectrum of antimicrobial activity against gram-
positive and -negative bacteria, and play an essential role in the innate immune response 
as antimicrobial and immune-modulating agents [174].  
Owing to their multiple functions, AMPs could act as effective agents in bacterial infected 
wounds, since the disruption of the skin barrier allows pathogens to attack the body and 
thus drastically increases the risk of infection.  
Until now, pexiganan, a 22 amino acid long peptide analogue of the naturally occurring 
AMP, magainin 2, isolated from the skin of the African clawed frog, Xenopus laevis [61], is 
the first AMP evaluated for the treatment of infected human wounds, particularly for the 
treatment of diabetic foot ulcer [100]. Unfortunately, the use of pexiganan failed the Phase 
III clinical trial in 2016. 
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1.4 Peptides used within the thesis 
1.4.1 The cationic cell-penetrating peptide sC18 
The cell-penetrating peptide sC18 is a highly cationic fragment (amino acid residues 106 – 
121) of the C-terminus of the 18 kDa cationic antimicrobial protein CAP18, and highlighted 
as a useful delivery vehicle for cytostatic compounds [62, 79, 130, 172]. Furthermore, sC18 
was shown to efficiently internalize into cells which might be attributed to its amphipathic α-
helical nature [130, 183]. The major uptake route of sC18 is proposed to follow the energy-
dependent endocytotic pathway. However, previous studies demonstrated that structural 
modifications of sC18, particularly the cyclization of the peptide backbone and the 
dimerization of the peptide sequence resulting in a branched version, lead to an efficient 
and moreover increased cellular uptake showing somehow a certain selectively towards 
cancerous cells [68, 77, 78].  
Furthermore, a study by Splith et al. showed the successful delivery of a novel designed 
sC18 conjugate composing of a nitroimidazole unit (NIA) as radiosensitizer, a radioactive 
label and sC18 as transporter, to target hypoxic tumor tissues [173]. Lately, Bergmann et 
al. improved this delivery vehicle by introducing D-amino acids instead of L-amino acids, 
leading to a proteolytically more stable peptide, since this system was hampered by fast 
degradation [18].  
The following table represents an extract from sC18 variants, which were applied for various 
approaches. 
Table 2. An extract from sC18 variants for diverse application approaches. B: L-propargylglycine, X: L-(Ɛ-azido)-lysine; 
___: amino acids involved in cyclization; NIA: 2-(2-nitroimidazol-1-yl)acetic acid 
Peptide  Sequence Features Ref. 
sC18 GLRKRLRKFRNKIKEK Transport tool for 
cytostatic drugs, e.g. 
metal complex and 
imaging probes  
[130, 
152, 
172] 
(sC18)2                             GLRKRLRKFRNKIKEK 
GLRKRLRKFRNKIKEK 
Drug delivery, 
tumor-selectivity 
[68, 
78] 
cyc3 BLRKRLRKFRNX Vehicle for gene 
delivery 
[77] 
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DOTA-
sC18(NIA)  
DOTA-βA-GLRK(NIA)RLRKFRNKIKEK Specific targeting of 
hypoxic tumor tissue 
[173] 
NODAGA-
DsC18(NIA)2 
NODAGA-βA-GLRK[(βA)2-
(NIA)]RLRKFRNK[(βA)2-(NIA)]IKEK 
[18] 
 
Overall, the cationic sC18 peptide provides a highly attractive tool through which bioactive 
molecules can reach their intracellular target.  
1.4.2 The naturally derived peptide Tylotoin 
Tylotoin, a short peptide consisting of 12 amino acid residues, was recently identified and 
extracted from the skin of the salamander Tylototriton verrucosus [126]. The precursor of 
Tylotoin was found to belong to the family of cathelicidin, which is a conserved protein family 
among vertebrates [126]. More precisely, Tylotoin is derived from the C-terminal part, like 
other antimicrobial peptides, e.g. LL-37 [2] or sC18 [130] but in contrast to these peptides, 
Tylotoin exhibits no antimicrobial activity [126]. However, the main feature of Tylotoin is 
provided by its ability to significantly accelerate the healing of full-thickness wounds in mice 
indicating that topical application of Tylotoin has a potent healing effect on full-thickness 
skin wounds [126]. Thereby, the short peptide was shown to directly function in the migration 
and proliferation of fibroblasts, keratinocytes, and vascular endothelial cells, which are all 
important key cell types during the wound healing process [126, 169].  
With this potent peptide in hand, another step towards the understanding of the cellular and 
molecular events underlying the rapid wound healing process in salamanders could be 
done, which might lead to the development of rapid wound healing therapies in the future.
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2. Aims of the thesis  
The primary goal of this thesis was to understand the initial step of cell-penetrating peptides 
cell entry in more detail on a molecular level. At the same time, model membrane systems 
have gained increased attractiveness and thus were used to establish different techniques 
that can be helpful to shed light on the action mechanism of CPPs. The second chapter 
focuses on the design, characterization and the application of cell-penetrating peptide 
conjugates in skin wound healing.  
2.1 Establishment of diverse bilayer model systems and their 
applications in peptide-lipid interactions 
In this chapter, different model membrane systems, more precisely large and giant 
unilamellar vesicles and membrane vesicles, which are exclusively derived from live cells 
plasma membranes, were employed to evaluate peptide-membrane interactions and their 
significance for the successful translocation across the cell membrane. For this purpose, 
various methodologies are described that have been established in our working group by 
myself, and which represent particularly great tools to assess the relationship between 
peptides and various membrane components to understand the molecular level of 
translocation of CPPs. More specifically, great attention is paid to aspects concerning 
peptides effect on membrane integrity, structural behavior of peptides in the presence of 
lipid bilayer systems and finally, the elucidation of the relevance of mammalian plasma 
membrane compositions. Thus, these newly acquired techniques were then applied using 
two different structural modified variants of the cationic cell-penetrating peptide sC18 to 
unravel how CPPs interact with live cells on a molecular level using artificial membrane 
systems.  
2.2 CPPs and wound healing 
So far, no study of which we are aware has been reported on the use of CPPs in the 
application field of human skin wound healing. Thus, for the first time, a cell-penetrating 
peptide was covalently conjugated to a wound healing promoting peptide with the main goal 
to accelerate the wound healing process. Herein, these novel conjugates were evaluated 
upon their cytotoxicity, cellular internalization behavior and moreover, the impact of peptides 
on in vitro wound healing was investigated. 
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3. Materials and methods 
The chemicals, reagents and consumables used in this present thesis were obtained from 
the companies Merck (Darmstadt, Germany), Sarstedt (Nümbrecht, Germany), Sigma-
Aldrich (Taufkirchen, Germany) and VWR (Darmstadt, Germany), unless otherwise 
specified. Nα-Fmoc protected amino acids were purchased from IRIS Biotech (Marktredwitz, 
Germany). 
The following table depicts the applied equipment during the working time. 
Table 3. An overview about the equipment used during the thesis. 
Instrument Producer 
Balance Analytical balance FA-210-4,  
Faust Laboratory balance SBA52, Scaltec 
Blotting system kuroGEL semi-dry-blotter, VWR 
CD spectrometer JASCO J-715 spectropolarimeter 
Cell culture clean bench Hera Safe 
Centrifuges Thermo Scientific; Heraeus Multifuge X1R  
Thermo Scientific; Heraeus Pico 17  
CO2-incubator BINDER 
Electrophoresis system Mini-PROTEAN Tetra Vertical Electrophoresis System; 
Bio-Rad 
ESI mass spectrometer Bruker Esquire HCT 
Flow cytometer Guava® easyCyte flow cytometer, Merck, Darmstadt 
BD Accuri C6 flow cytometer, Heidelberg  
Haemocytometer Neubauer improved, superior Marienfeld 
Heating block Eppendorf – Thermomixer compact 
HPLC (analytic) Chromolith Performance column (RP-18, 130 Å, 2 µm, 
100 × 4.60 mm, Merck 
HPLC (preparative) Elite Lachrom Hitachi Pump L-2130, Elite 
Lachrom Hitachi Autosampler L-2200, Elite 
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Lachrom Hitachi Diode Array Detector L-2455, 
Teledyne ISCO Fraction Collector Foxy R1, 
Column: Phenomenex Jupiter, 4 µm Proteo 90 Å, 250 
x 15 mm  
LC-mass spectrometer LC: Hewlett Packard Series 1100 
MS: Finnigan MAT-LCQ 
Lyophilizer Lyovac GT2 with CertomaT SII 
Thermo Savant Refridgerated Vapor Trap RVT5105 
Microscope Inverted microscope (Motic AE31, Wetzlar)  
Confocal laser scanning system (Nikon D-Eclipse C1)  
Mini-extruder Avanti Polar Lipids Inc., Alabaster, USA 
Multipette® plus Eppendorf 
PCR Thermal Cycler FlexCycler, Analytik Jena, Jena, Germany 
Pipettes Eppendorf Research 
Pipetting aid NeoLab 
Plate reader Tecan infinite M200, Salzburg, Austria 
Rotary evaporator VWR 
Rotary Shaker KL-2, Edmund Bühler GmbH 
Certomat H/SII, Braun Biotech, Göttingen, Germany 
Spectral photometer Thermo Scientific Genesys 10S UV-Vis 
Speed-Vac Thermo Scientific Speedvac Concentrator Savant 
SC210A, RVT5105 Refrigerated Vapor Trap 
VLP80 Vacuum Pump 
Synthesis roboter MultiSynTech Syro I, Bochum, Germany 
Thermomixer compact Eppendorf 
Vacuum pump VWR 
Vortex Scientific Industries – Vortex Genie 2 
Water bath Julabo SW22 
XcelVapTM Horizon Technology 
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3.1 Peptides and lipids 
3.1.1 Peptides 
All peptides used in this work and their sequences are listed in Table 4. 
Table 4. Sequences and references of investigated peptides. All peptides are amidated at the C-terminus and N-terminally 
labeled with 5(6)-carboxyfluorescein B: L-propargylglycine, X: L-(Ɛ-azido)-lysine; ___: amino acids involved in cyclization. 
Peptide Sequence Reference 
sC18 GLRKRLRKFRNKIKEK [68, 78, 130] 
sC18* GLRKRLRKFRNK [77] 
(sC18)2 
                              GLRKRLRKFRNKIKEK 
  GLRKRLRKFRNKIKEK 
[68, 78] 
lin(sC18)2 GLRKRLRKFRNKIKEKGLRKRLRKFRNKIKEK 
[129],  
this work 
(sC18*)2 
                      GLRKRLRKFRNK 
  GLRKRLRKFRNK 
lin(sC18*)2 GLRKRLRKFRNKGLRKRLRKFRNK 
cyc1 BLRXRLRKFRNK [77] 
cyc2 BLRKRLRXFRNK [77] 
cyc3 BLRKRLRKFRNX [77] 
Tylotoin KCVRQNNKRVCK [126] 
rTylotoin RNCVKKNCRVKQ 
this work 
Tylotoin-sC18 KCVRQNNKRVCKGLRKRLRKFRNKIKEK 
sC18-Tylotoin GLRKRLRKFRNKIKEKKCVRQNNKRVCK 
Tylotoin-sC18* KCVRQNNKRVCKGLRKRLRKFRNK 
sC18*-Tylotoin GLRKRLRKFRNKKCVRQNNKRVCK 
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3.1.2 Lipids 
All lipids used in this study are depicted in Table 5.  
Table 5. Lipids used in this study were obtained as chloroform solution (10 mg/ml). 
Lipid Company 
1,2-dioleoyl-sn-glycero-3-[phospho-L-serine] 
(DOPS) 
Avanti Polar Lipids, Inc. (Alabaster, 
USA) 
1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (DOPG) 
Avanti Polar Lipids, Inc. (Alabaster, 
USA) 
1,2-dioleoyl-sn-glycero-3-
phophoethanolamine (DOPE) 
Avanti Polar Lipids, Inc. (Alabaster, 
USA) 
1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) 
Avanti Polar Lipids, Inc. (Alabaster, USA) 
Atto550 labeled DOPE Atto Tec (Siegen, Germany) 
cholesterol (Chol) Sigma-Aldrich (Taufkirchen, Germany) 
L-α-phosphatidylinositol-4,5-bisphosphate 
(porcine brain, PIP2) 
Avanti Polar Lipids, Inc. (Alabaster, 
USA) 
sphingomyelin (porcine brain, SM) Jena Bioscience (Jena, Germany) 
 
3.2 Solid phase peptide synthesis (SPPS) 
The peptides used in this thesis were synthesized via automated solid phase peptide 
synthesis as described below. 
3.2.1 Automated solid phase peptide synthesis 
Automated solid phase peptide synthesis offers a suitable strategy to produce chemical 
engineered peptides simultaneously. The peptides used were synthesized on a multiple 
Syro I peptide synthesizer following the Fmoc/t-Bu strategy. The synthesis runs in open 
polypropylene reactor vessels (2 ml syringes) equipped with a fritted disc. The software 
SyroXP calculates the amounts of amino acids (0.4 mol/l) and solvents required for the 
complete synthesis run. In order to synthesize a peptide amide, Rink amide resin 
(NovaBiochem, Bad Soden, Germany) was used. The Fmoc-protected Rink amide resins 
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(30 mg, 0.5 mmol peptide per gram resin; 15 µmol ≙ 1 eq.) were first swollen in DMF, then 
the Fmoc protecting groups were cleaved with 40% piperidine in DMF and following another 
deprotection step/cleavage with 20% piperidine in DMF. After four washing steps using 
DMF, the Nα-Fmoc protected amino acids were introduced in 8-fold excess by using a 
double coupling procedure and in situ activation with Oxyma and DIC. In a last step, when 
the defaulted amino acid sequence of the peptides was completed, the N-terminal Fmoc-
protecting group was removed under previously mentioned conditions and the resin was 
washed with DMF. A reaction scheme of the automated solid phase peptide synthesis is 
illustrated in Figure 11.  
 
Figure 11. Schematic overview of general steps in solid phase peptide synthesis. R: different side-chains of amino 
acids. PG: protecting groups of amino acid side chains. 
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3.2.2 5(6)-carboxyfluorescein (CF) – labeling on resin 
To allow microscopic and flow cytometric analysis, the peptides were N-terminally labeled 
with 5(6)-carboxyfluorescein. The labeling procedure was performed while the peptides 
were still bound to the resin with fully protected side chains. Thus, the resin was swollen in 
1 ml DMF for at least 15 min. After the solvent was removed, 3 eq. of CF and HATU were 
dissolved in 300 µl DMF and added to the swollen resin. Subsequently, 3 eq. of DIPEA were 
added directly to the syringe and the reaction was carried out under vigorous shaking for 
2 × 2 h at RT or overnight with 5 eq. of Oxyma and DIC. After the incubation time, the resin 
has been washed five times with DMF, CH2Cl2, MeOH and Et2O and finally dried for 10 min 
in a Speed-Vac. To monitor whether the coupling was successful, a Kaiser test was 
performed. CF-polymers, which might have formed, were cleaved by treatment with 20% 
piperidine for 45 min. 
3.2.3 Kaiser test [88] 
In Fmoc solid phase peptide synthesis, monitoring the completeness of the coupling step is 
mandatory. Therefore, the Kaiser test is used to control the presence or absence of free 
amino groups based on the reaction of ninhydrin with amines. Therefore, a few resin beads 
were placed in a 1.5 ml reaction vessel and one drop of each solution (I, II and III; Table 6) 
was added consecutively. The samples were incubated at 95 °C for 5 min. A blue coloring 
of the resin beads and the solutions indicates free amino groups and hence an incomplete 
coupling, whereas a yellowish color represents no free amino groups and therefore a 
negative result. As a positive control the primary amine ethanolamine was chosen. 
Table 6. Compositions of the solutions required for the Kaiser test. 
Solution Composition 
Solution I 1.0 g ninhydrin in 20 ml EtOH 
Solution II 80.0 g phenol in 20 ml EtOH 
Solution III 0.4 ml KCN solution in 20 ml piperidine 
3.2.4 Sample cleavage 
To verify the success of the coupling reaction, it is advisable to perform a sample cleavage. 
Therefore, 2.5 µl of triisopropylsilane (TIS) and 2.5 µl of water, working as scavengers, were 
added to a small amount of resin beads. In the case of Tylotoin conjugates containing 
cysteine within the sequence, 7 µl of thioanisole and 3 µl of 1,2-ethandithiol (EDT) must be 
used as scavengers. Afterwards, the mixture was filled up to 100 µl with TFA and the 
reaction was carried out under shaking conditions for 3 h at RT. After the incubation time, 
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1 ml of ice-cold diethyl ether was added to the mixture to precipitate the peptide and was 
left for 20 min or overnight at -20 °C. Afterwards, the mixture was washed with 1 ml diethyl 
ether and centrifuged (4 °C, 4 min at 10,000 x g) for at least five times until no scavenger 
smell was perceived. The resulting pellet was finally dried for 10 min in the Speed-Vac and 
dissolved in 100 µl H2O/t-BuOH (3:1, v/v). Finally, the sample was analyzed by HPLC-ESI-
MS. 
3.2.5 Full cleavage of peptide 
The peptide amides were cleaved with a mixture of TFA/TIS/water (95:2.5:2.5, v/v/v) except 
for Tylotoin conjugates, which were cleaved by a mixture of TFA/thioanisole/EDT (90:7:3, 
v/v/v) within 3 h as previously described. The peptides were precipitated from cold diethyl 
ether (10 ml) at -20 °C and collected by six centrifugation steps (4 °C, 4 min at 5,000 x g) 
and lyophilized from water/t-BuOH (LyoVac GT2, Leybold, Germany). A sample of the 
peptide solution was analyzed by HPLC-ESI-MS. 
3.3  Peptide analysis 
3.3.1 Analytical HPLC-MS 
A high-performance liquid chromatography electrospray ionization mass spectrometry 
(HPLC-ESI-MS) method was used to evaluate the purity and the identity of the peptides. 
Therefore, the peptide solution was diluted with a starting gradient of 10% ACN in water 
with 0.1% formic acid (FA). 10 µl of the solution was injected and separated by an ACN 
gradient which was raised from 10 to 60% by the HPLC. The flow rate was set to 0.6 ml/min. 
The analytics were performed on an Elite LaChrom VWR-Hitachi system using a Chromolith 
Performance column (RP-18, 130 Å, 2 µm, 100 × 4.60 mm, Merck). One part of the eluate 
was passed to the electrospray ionization source whereby ions were generated and their 
m/z ratio was determined. 
3.3.2  Preparative RP-HPLC 
Purification of the peptides was achieved by preparative RP-HPLC on a Phenomenex 
Jupiter column (Proteo, 90Å, 4 µm, 250 × 15.00 mm) using a linear gradient of 10 – 60% B 
in A (A = 0.1% TFA in water; B = 0.08% TFA in ACN) over 45 min and a flow rate of 6 ml/min. 
The peptides were detected at 220 nm and the fractions were collected separately. 
Afterwards, the peptide solution was removed from ACN using either the Speed-Vac or the 
XcelVap™ and then lyophilized overnight. 
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3.3.3  Circular dichroism (CD) spectroscopy 
The CD spectra were recorded from 260 nm to 180 nm in 0.5 nm intervals at 20 °C using a 
JASCO J-715 spectropolarimeter in a N2 atmosphere. Peptide solutions were dissolved in 
10 mM potassium phosphate buffer (pH 7.0) containing either 0 or 50% (v/v) trifluoroethanol 
(TFE) to a final peptide concentration of 20 µM. The CD spectra were measured using a 
1 mm quartz cell and each measurement was repeated three times. Instrument parameters 
were set as follows: sensitivity, 100 mdeg; scan mode, continuous; scan speed, 50 nm/min; 
response time, 2 s and bandwidth, 1.0 nm. All CD spectra were smoothed and corrected by 
subtraction of the CD spectrum form the respective buffer to eliminate potential 
measurement errors caused by the solvents. The ellipticity was expressed as molar 
ellipticity [Θ] in 
𝑑𝑒𝑔×𝑐𝑚2
𝑑𝑚𝑜𝑙
. 
3.4 Peptide-lipid interactions 
3.4.1 Preparation of large unilamellar vesicles (LUVs) 
For the preparation of different composed LUVs, several lipids were required, which are 
dissolved in CHCl3. To remove residual solvent, the lipid mixture was placed in a round-
bottomed flask under vacuum at 37 °C for at least 1 h to remove residual solvent. The dried 
lipid film was either hydrated with HKS-glucose buffer (for flow cytometric studies and CF-
release experiments) or with 25 mM phosphate buffer, pH 7.4 (for CD spectroscopic 
studies) at 45 °C for 5 min to form liposomes with a final concentration of 2 mM (CD 
spectroscopic analysis), 4 mM (flow cytometric studies) or 8 mM (CF-release experiments). 
To form LUVs, the resulting multilamellar vesicle (MLV) dispersion was subsequently run 
through 10 freeze/thawing cycles and passed 21 times through a mini-extruder equipped 
with a 0.4 µm polycarbonate track-etch membrane (Avanti Polar Lipids, Inc.). Liposome 
preparations were analyzed by dynamic light scattering indicating a range of 250 – 400 nm 
in diameter. 
HKS-glucose buffer 
HEPES 25 mM (pH 7.4) 
KCl  150 mM 
Sucrose 10% 
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Table 7. All lipid compositions used during the thesis. For peptide-induced CF-leakage, LUVs entrapping 100 mM CF 
were prepared. The vesicle membranes were labeled with 0.2 mol% Atto550-DOPE for flow cytometric studies. 
 
LUV 
compositions 
  Lipids [mol%]  
zwitterionic  anionic    
DOPC DOPE DOPG Sphingomyelin 
 
Cholesterol 
 
I 50 50  -  -  - 
 II 40 30  30 -  -  
 III 25 - 5 50  20  
 IV 37.5 37.5 5 -  20  
 V 22.5 22.5 5 50  -  
 
3.4.2 Preparation of giant unilamellar vesicles (GUVs) 
Giant unilamellar vesicles were generated as previously described [76, 148]. Briefly, super 
low melting agarose (1%, w/v) was coated on a clean glass slide and dried on a hot plate 
(∼50 °C) for 30 min. Afterwards, 10 µl of the respective lipid solution was spread on the 
agarose film and dried in vacuo for at least 1 h to remove residual chloroform. To visualize 
the membranes, the lipid solution was prior doped with 0.2 mol% Atto550-DOPE. Then, a 
seal ring was placed onto the lipid coated areas on the slide to obtain two sealed chambers. 
For the preparation of GUVs encapsulating the blue dye Oyster 405 (Luminaris GmbH, 
Münster, Germany), dextran buffer containing additionally 5 μM of Oyster 405 (300 μl each) 
was added to the hybrid film. The glass slide was then left in the dark for 2 h to allow 
hydration and swelling of the lipids. To harvest the GUV suspension, the glass slide was 
gently tilted in all directions to detach the liposomes from the surface. The giant liposomes 
were then stored in LoBind tubes (1.5 ml, Eppendorf, Hamburg, Germany) at RT and were 
used within three days. 
Dextran buffer 
HEPES 10 mM (pH 7.4) 
KCl  50 mM 
NaCl  50 mM 
Dextran 1 mg/ml (from Leuconostoc spp., 6 kDa) 
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Table 8. All lipid compositions used during the thesis. The vesicle membranes were labeled with 0.2 mol% Atto550-DOPE 
or with 0.2 mol% DiI to visualize the loosely packed liquid-disordered lipid phase (Ld).  
 
GUV 
compositions 
 Lipids [mol%]  
zwitterionic  anionic    
DOPC DOPE DOPG Sphingomyelin 
 
Cholesterol 
 
I 50 50  -  -  - 
 II 40 30  30 -  -  
 III 25 - 5 50  20  
 IV 37.5 37.5 5 -  20  
 V 22.5 22.5 5 50  -  
 
3.4.3 Preparation of giant plasma membrane vesicles (GPMVs) 
Cells (HEK-293 800,000; MCF-7 250,000) were seeded in a 6-well culture plate (Sarstedt, 
Nümbrecht, Germany) and were grown to 70 – 80% confluency in appropriate growth 
medium supplemented with 4 mM L-glutamine and 10% fetal bovine serum (FBS). Giant 
plasma membrane vesicles (GMPVs) were prepared as described earlier by R. E. Scott, 
1976 [162] with minor modifications. First, the cells were washed twice with GPMV buffer. 
To induce the formation of cell-free vesicles, 1 ml of freshly prepared GPMV buffer 
supplemented with paraformaldehyde (PFA) and dithiothreitol (DTT) at final concentrations 
of 25 mM and 2 mM respectively were added and the cells were incubated for 2 h at 37°C 
while slowly shaken (60 rpm, Certomat H/SII, Braun Biotech). After incubation, the GPMV-
rich cellular supernatant was transferred into a 15 ml conical tube, where the GPMVs were 
allowed to settle down on ice for 30 min. Afterwards, 20 – 50% of the total volume were 
transferred from the bottom of the conical tube into a 1.5 ml Eppendorf tube. For microscopic 
studies, 0.5 µg/ml DiI stain (final concentration, in EtOH) was added and incubated for 
15 min at 37 °C. After isolation, GPMVs were stored at 4 °C for 1 – 2 days without visible 
degradation.  
GPMV buffer 
HEPES 10 mM (pH 7.4) 
NaCl  150 mM 
CaCl2  2 mM  
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3.4.4 Secondary structure via CD spectroscopy 
In the presence of LUVs, the peptide to lipid molar ratio in the cuvette was set to 1/50 and 
the instrument settings were chosen as described in section 3.3.3. All CD spectra were 
averaged over three scans, smoothed and the background was subtracted from the signal, 
respectively. The ellipticity was expressed as molar ellipticity [Θ] in 
𝑑𝑒𝑔×𝑐𝑚2
𝑑𝑚𝑜𝑙
. 
3.4.5 Peptide-induced CF-release 
CF-containing LUVs were prepared by hydrating a dried lipid film (8 mM) of desired 
compositions with HKS-glucose buffer containing 100 mM CF. The fluorescence intensity 
in the presence of 100 mM CF is low due to self-quenching but increases upon dilution. 
Free CF outside the LUVs was separated by size exclusion chromatography using a PD10 
column (GE Healthcare). Then, peptides were added to LUVs and the release of CF from 
vesicles was monitored by measuring the increase in fluorescence intensity using the Tecan 
infinite M200 plate reader. At the end of each experiment, Triton X-100 (0.4% (w/v) final 
concentration) was applied to measure the maximum of dequenching that will be used to 
normalize data. The percentage of CF release was determined by the following equation 
% 𝐶𝐹 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =  
𝐹(𝑡) − 𝐹0 
𝐹𝑓 − 𝐹0
∗ 100 
where F(t) is the fluorescence intensity at time t, F0 is the fluorescence intensity before 
peptide addition and Ff is the fluorescence intensity after the final addition of Triton X-100.  
3.4.6 Flow cytometric binding studies  
Various compositions of LUVs (4 mM) were applied to flow cytometry analysis as recently 
described by the Nickel group [180]. CF-labeled peptides were added to 25 µl solutions of 
LUVs and incubated at 25 °C for 2 h while mild shaking (450 rpm, Thermomixer compact, 
Eppendorf, Hamburg, Germany). After incubation, the peptide/liposome solutions were 
washed with 1 ml buffer (150 mM KCl, 25 mM HEPES, pH 7.4) and centrifuged at 15,000 x g 
for 10 min at 4 °C. The supernatants were carefully removed and the pellets resuspended 
in 400 µl buffer solution. Afterwards, the peptide/lipid interactions were analyzed with a 
fluorescence-activated cell sorter (FACS) instrument (BD Accuri C6 flow cytometer). 
3.4.7 Confocal laser scanning microscopy 
Microscopic studies with GUVs were performed as recently described by our working group 
[148]. Briefly, GUVs loaded with the membrane-impermeant fluorophore Oyster 405 were 
prepared as described in section 3.4.2. To remove untrapped Oyster 405, liposomes were 
centrifuged two times at 14,000 x g for 10 min at RT. A 40 μl aliquot of the GUV solution 
was diluted in 50 μl of the respective buffer without Oyster 405 and was then transferred 
Materials and Methods 
28 
into a tissue culture vessel (FlexiPERM slide, 8 wells, Sarstedt, Germany). CF-labeled 
peptides diluted in Dextran buffer were added to the outer solution of GUVs at a final 
concentration of either 10 or 20 μM. The GUV−peptide interaction was analyzed using a 
confocal laser scanning system (Nikon D-Eclipse C1) consisting of an inverted microscope 
(Nikon Eclipse Ti) equipped with a 20× objective (NA 0.45, Plan Fluor; Nikon). Microscope 
pictures were recorded in 16-bit grayscale, pseudocolored in red (channel 1), green 
(channel 2), and blue (channel 3) followed by processing with ImageJ.  
GPMVs were analyzed by CLSM as described by the Pooga group with minor modifications 
[10]. Concisely, after labeling the vesicles with the fluorescence stain DiI, the CF-labeled 
peptides at 1 µM concentrations were immediately added to GPMV suspension and 
incubated at RT for 1 h. Then, 20 µl of the peptide/membrane solution were deposited onto 
a µ-slide 8-well (Ibidi) plate and covered with glass cover slips (∅ 9 mm, round, No 1). The 
GPMVs were investigated using a Nikon Eclipse Ti confocal laser scanning microscope 
equipped with a 60× oil-immersion objective. Images were recorded with Nikon EZ-C1 
software and adjusted equally with ImageJ software. 
3.5 In vitro studies 
3.5.1 Microorganisms and media 
The strain numbers and sources of the bacteria used in this thesis are Micrococcus luteus 
(DSM 20030) and Salmonella typhimurium (TA 100). 
For both bacterial strains, Mueller Hinton broth agar plates were used for maintenance und 
broth medium was used to carry out antimicrobial activity studies. 
Mueller Hinton Broth 
Acid casein peptone 17.5 g/l 
Beef infusion  2.0 g/l 
Corn starch  2.5 g/l 
For Mueller-Hinton Broth agar plates, 15 g/l of bacteriologic agar was additionally 
supplemented. 
3.5.2 Antimicrobial activity 
The determination of the antimicrobial activity of peptides against gram-positive and gram-
negative bacteria was conducted using the p-iodonitrotetrazolium-chloride (INT) violet 
assay. INT is a tetrazolium based reagent which is converted to a pink formazan dye in the 
presence of metabolically active bacteria. 
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Therefore, M. luteus and S. typhimurium were cultured in Mueller Hinton broth overnight at 
37 °C while mild shaking (180 rpm). Overnight-cultured bacteria were added into fresh 
medium, grown to an optical density at 600 nm of 0.7, and 10 µl bacterial solution were 
added in triplicate to wells of a 96-well plate (BD Falcon, USA). The peptides used at 
variable concentrations (0.25 – 25 µM) and 180 µl of Mueller Hinton medium were added 
to each corresponding well and incubated for 6 h at 37 °C. 70% EtOH served as positive 
control and H20 was used as negative control. After the incubation time, 10 μl of the freshly 
prepared INT solution (1 mg/mL in DMSO) were added to each well and incubated for 
further 30 min at 37 °C. The viability of bacteria relative to untreated control was determined 
by measuring the absorption at 540 nm on a Tecan infinite M200 plate reader.  
3.5.3 Cell lines and culture conditions 
The cell lines used in this thesis included: HaCaT (Human adult low Calcium high 
Temperature keratinocytes), HEK-293 (human embryonic kidney cells), HeLa (human 
cervix carcinoma cells) and MCF-7 (human breast adenocarcinoma cells). Cells were 
cultivated in sterile 10 cm petri dishes (100 x 200 mm, BD Flacon) at 37 °C and 5% CO2 in 
a humidified atmosphere. HaCaT cells were cultured in Dulbecco’s modified Eagle medium 
(DMEMg) complemented with 4500 mg/l glucose, 10% FBS and 2 mM L-glutamine. For 
HEK-293 cells, complete DMEM media supplemented with 15% FBS and 4 mM L-glutamine 
was used. HeLa and MCF-7 cells were grown in complete RPMI 1640 medium containing 
additionally 10% FBS and 4 mM L-glutamine. 
3.5.4 Maintenance and seeding cells 
All cell culture work was done under sterile conditions with autoclaved materials under a 
clean bench, equipped with a hood. Once a year, all cell lines were tested for mycoplasma 
contaminations according to manufactures protocol (PCR Mycoplasma Test Kit II, 
Applichem, Darmstadt). 
To cultivate the cell lines, they were split normally twice a week. Therefore, the medium was 
discarded and the cell layer was washed twice with PBS. Then, 1 ml of porcine trypsin 
solution (0.5 mg/ml in Hank´s balanced salt solution) was added to the culture dish and 
incubated at 37 °C till the cells have rounded up and begun to detach. Subsequently, the 
cells were resuspended in 9 ml of the appropriate FBS-containing culture media to block 
trypsin activity, transferred to new culture dishes and mixed with fresh medium depending 
on the certain split ratio. HEK-293 cells were not cultivated above the 30th passage; MCF-7 
and HeLa cells not over 40th. 
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3.5.5 Freezing and thawing cells 
To store cells for future studies, cryopreservation provides a great tool. Therefore, confluent 
cells were trypsinized and then centrifuged for 5 min at 300 x g. The cell pellet was 
resuspended in 1.5 ml appropriate medium containing FBS and additionally 10% of sterile-
filtered DMSO. Afterwards, the cells were transferred to cryogenic vials and cooled down to 
4 °C for 15 min and then kept at -20 °C for further 2 h. Next, the cells were incubated 
overnight at -80 °C and finally stored in liquid nitrogen. 
To thaw cryopreserved cells, the frozen cells were defrosted rapidly in a 37 °C water bath 
and directly transferred to a culture dish containing the required pre-warmed medium with 
FBS. In case of HaCaT cells, the cells were first transferred to a 15 ml tube containing 
complete growth media, centrifuged for 5 min at 300 x g and finally moved to a 25 cm2 flask. 
The cells were incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. The next 
day, the cells were washed twice with PBS to get rid of remaining DMSO and dead cells 
and finally maintained in appropriate complete growth media. 
3.5.6 Cell viability assays 
In order to examine possible cytotoxic effects of peptides on the cell viability, the following 
assays were applied. 
Resazurin-based Assay 
For a resazurin-based cell viability assay, 35,000 HeLa cells were seeded in triplicate onto 
a 96-well plate, grown to 70 – 80% confluency and incubated with various concentrations 
of peptides in appropriate growth medium without serum for 24 h under standard growth 
conditions. For the positive control, cells were treated with 70% ethanol for 10 min. After 
washing with PBS, resazurin stock solution (5% resazurin in PBS) was diluted with 
appropriate serum-free medium (1:10, v/v) and 100 μl of this solution was incubated with 
the cells for further 1 h at 37 °C. Subsequently, the cell viability was determined relative to 
untreated cells by measurement of the resorufin product at 595 nm (λex = 550nm) on a 
Tecan infinite M200 plate reader.  
Tetrazolium-based Assay 
The toxic effect of peptides on HaCaT cells was evaluated using the 3(4,5-dimethylthiazol-
2yl)2,5-diphenyltetrazolium bromide (MTT) colorimetric method. MTT is a tetrazolium salt 
which is reduced to a purple colored formazan product by mitochondrial reductases, present 
only in metabolically active cells. The intensity of the color is directly proportional to the 
number of metabolically-active cells. Keratinocytes were seeded in triplicate onto a 96-well 
plate at a density of 80,000 cells per well in DMEMg supplemented with 2 mM L-glutamine 
and 2% FBS. After overnight incubation at 37 °C and 5% CO2 atmosphere, the medium was 
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replaced with 100 μl fresh serum-free media containing the peptides at different 
concentrations. After 24 h of incubation, 10 µl of MTT (0.45 mg/ml final, in PBS) were added 
to each well. After 4 h of incubation, the supernatants were removed and the formazan 
crystals were dissolved by adding 100 μl of dimethyl sulfoxide (DMSO). As positive control, 
cells were treated with 70% EtOH for 10 min. The absorption was measured at 570 nm and 
at a reference wavelength of 630 nm using a plate reader (Tecan infinite M200). Cell viability 
was expressed as percentage of viability in control cells (cells not treated with peptide). 
3.5.7 Internalization studies 
Confocal microscopic uptake studies  
Cells were seeded in a µ-slide 8-well (Ibidi) plate (HaCaT 90,000; HEK-293 100,000; HeLa 
45,000 and MCF-7 50,000) and grown to 70 – 80% confluency. Then, the cells were 
incubated with CF-labeled peptides in serum-free medium for the requested time at either 
4°C or 37 °C as indicated. The nuclei were stained for 10 min with 0.6 µl Hoechst 33342 
nuclear dye (bisbenzimide H33342, 1 mg/mL in H2O, sterile filtered) prior to the end of 
peptide incubation. Finally, the solution was removed and the cells were treated for 30 s 
with 150 µl trypan blue (150 µM in 0.1 M acetate buffer, pH 4.15) for quenching the external 
fluorescence. After washing twice with PBS, 300 µl of FBS-containing cell culture medium 
were added to each well. Images were taken by using a Nikon Eclipse Ti confocal laser 
scanning microscope equipped with a 60x oil-immersion objective (N.A. 1.4, Plan APO VC, 
Nikon). Images were recorded with Nikon EZ-C1 software and adjusted equally with ImageJ 
software. 
For cholesterol depletion, 300 µl of a 10 mM freshly prepared methyl-β-cyclodextrin (MβCD) 
solution dissolved in appropriate serum-free medium were added to the cells and incubated 
for 1h at 37 °C. Subsequently, the cells were washed once with PBS and then treated as 
described above. 
For treatment with endocytosis inhibitor, 80 µM of dynasore (in serum-free medium, 297 µl) 
was added to the cells. After 1 h of incubation at 37 °C, 3 µl of a 1 mM CF-labeled peptide 
solution was added and incubated for further 30 min. Afterwards, the cells were handled as 
described above. 
For specific cell organelle trafficking, cells were incubated with 10 µM of CF-labeled 
Tylotoin-sC18* together with either 1 µM MitoTracker Red FM dye (1mM stock solution in 
DMSO, Molecular Probes) or 75 nM Lyso-Tracker (1 mM stock solution in DMSO, 
LysoTracker Red, Molecular Probes) for 120 min at 37 °C and continued as mentioned 
above. In case of staining the endoplasmic reticulum, 1 µM of ER-Tracker (1 mM stock 
Materials and Methods 
32 
solution in DMSO, ER-Tracker Red BODIPY, Molecular Probes) were added 15 min prior 
to the end of peptide incubation.  
Flow cytometric uptake studies 
Cells were seeded in triplicate in a 24-well plate (HaCaT 400,000; HEK-293 400,000; HeLa 
170,000; MCF-7 200,000) and grown to 70 – 80% confluency under normal growth 
conditions. After incubation at 37 °C for 30 min with CF-labeled peptides in serum-free 
medium, the cells were washed twice with PBS, trypsinized and resuspended in indicator-
free medium. Analyses were performed on a Guava® easyCyte flow cytometer (Merck, 
Darmstadt, Germany). Cellular autofluorescence was subtracted.  
For cholesterol depletion, 400 µl of a 10 mM freshly prepared MβCD solution dissolved in 
appropriate serum-free medium were added to the cells and incubated for 1h at 37 °C. 
Subsequently, the cells were washed once with PBS and then treated as described above. 
3.5.8 In vitro scratch assay 
The ability of peptides to promote the migration of keratinocytes was studied using an in 
vitro wound healing migration assay. Briefly, HaCaT cells suspended in DMEMg containing 
10% FBS were seeded in 12-well plates and grown until they reached confluence. Next, 
cells were starved in serum-free media for 16 h at 37 °C in a humidified atmosphere of 5% 
CO2. For inhibitor studies, mitomycin C (20 μM final, in serum-free medium) to prevent cell 
proliferation were added 90 min prior to scratch generation. After this, an artificial wound 
was created across cell monolayers by performing a vertical scratch with a sterile 200 µl 
pipette tip resulting in a cell-free area of approximately 100 - 200 µm. After washing twice 
with PBS to remove cell debris, the cells were treated with 13.5 µM peptides in serum 
containing medium. Untreated cells served as negative control and the human epidermal 
growth factor hEGF (5 ng/ml final, in serum-free medium) as positive control. Scratches 
were photographed immediately after peptide treatment and 7, 25 and 30 h after peptide 
addition using an inverted microscope at 10x magnification (N.A. 0.3, Plan Fluor, Nikon). 
Same image fields were captured and the cell-covered areas and migration speed were 
estimated by Wimasis Image Analysis. The experiments were repeated several times and 
representative pictures are shown. 
3.5.9 Western blot analysis 
For the detection of EGFR and p-EGFR, western blotting was performed. After reaching a 
confluence of 90 – 100%, HaCaT cells were split up into a 6-well plate and cultivated to 70 
– 80% confluency at 37 °C in an atmosphere with 5% CO2. In the following, cells were 
serum-starved for 16 h and then stimulated with Tylotoin-sC18* for 5, 15 and 25 min for 
detection of phospho-EGFR as indicated. The hEGF (100 ng/ml final, in serum-free 
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medium) served as positive control. For EGFR inhibition, cells were pretreated with 0.2 µM 
AG1478 for 10 min and subsequently treated with hEGF for 5 min. Afterwards, cells were 
harvested on ice in 1x cell lysis buffer (Cell Signaling Technology, Beverly, USA) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), collected by centrifugation 
at 4 °C and 10,000 x g for 10 min and protein concentration was determined via Bradford 
protein assay. Next, 20 µg samples were mixed with 1x Laemmli buffer and boiled at 95 °C 
for 5 min to denaturate the secondary and tertiary structures. Subsequently, the probes 
were separated on 10% SDS-PAGE (TGX™ FastCast™ acrylamide starter kit, 10%, Bio-
Rad, München, Germany) and transferred to a polyvinylidene difluoride membrane 
(Amersham™ Hybond™ P 0.45 µm, GE Healthcare, Solingen, Germany). Membranes were 
blocked with 5% skim milk in 1x TBS for 1 h while constant shaking. After three washing 
steps with 1x TBS, membranes were incubated with antibodies specific to EGFR and 
phosphor-EGFR (EGF Receptor (D38B1) XP Rabbit mAb; phospho-EGFR (Tyr1068) 
(D7A5) XP Rabbit mAb; (1:1000), Cell Signaling) overnight at 4 °C while gentle shaking and 
then treated with anti-rabbit horseradish-peroxidase (HRP)-conjugated secondary antibody 
(1:300, Cell Signaling) for 1 h. Then, blots were developed with SignalFire ECL reagent 
(Cell Signaling) and visualized by ChemiDoc MP imaging system (Bio-Rad). 
1x Laemmli buffer 
2-Mercaptoethanol  0.1% 
Bromophenol blue  0.0005% 
Glycerol   10% 
Sodium dodecyl sulfate 2% 
Tris-HCl   63 mM (pH 6.8) 
10x SDS buffer 
Tris-HCl   250 mM (pH 6.8) 
Glycine   1.92 M 
Sodium dodecyl sulfate 1% 
10x TBS buffer 
Tris-HCl   0.2 M (pH 7.6) 
NaCl    1.5 M 
10x Transfer buffer 
Tris-HCl   20 mM (pH 8.3) 
Glycine   192 mM 
Methanol   20% 
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4. Results and discussion 
4.1 Investigating CPP-lipid membrane interactions 
The first part of the thesis deals with the investigation of CPP-lipid membrane interactions 
that govern the initial step and subsequently the internalization of CPPs into cells. For this 
purpose, different assay systems had to be primarily established in our working group. In 
the first chapter, the several experimental approaches, which were employed in the thesis, 
are introduced and described in greater detail. In the second chapter, these novel 
established techniques were applied to gain knowledge of the mechanism of action of 
structural modified variants of the sC18 peptide.  
4.1.1 Experimental approaches on CPP-lipid membrane interactions 
Regardless of the many studies that were performed on cell-penetrating peptides, the 
mechanism of their cellular uptake is still not fully understood [111]. Therefore, there is an 
urgent need to unveil the mechanism of cellular translocation in greater detail to enable the 
development of effective transport vehicles, allowing the delivery of therapeutic compounds 
across the cell membrane [47]. However, the delivery of drugs through the membrane 
underlays complex biological processes, often difficult to understand due to their dynamic 
nature. In this regard, the use of model membrane systems has provided a great tool to 
recognize the role of lipids as well as membrane constituents within cellular interactions 
[137]. Thus, lipid membrane systems have become increasingly relevant in recent years 
[137].  
 
Figure 12. Scheme of cell membranes architecture [24] and model membrane systems. LUVs and GUVs mimic the 
arrangement of lipids in a cell membrane while GPMVs are deriving directly from the cells plasma membrane due to chemical 
induction. 
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Accordingly, Figure 12 illustrates different vesicle models used within the thesis as artificial 
mimetic systems for biological membranes to investigate peptide-lipid membrane 
interactions. As mentioned earlier, model membranes, in particular liposomes, are among 
the most important simplified systems in peptide-lipid interaction studies [137]. As indicated 
in Figure 12, unilamellar vesicles are ranging in size resulting in large unilamellar vesicles 
(LUVs) and giant unilamellar vesicles (GUVs). One of the major advantage of these vesicles 
is the possibility to choose a specific lipid composition of interest and thus selective 
investigations on peptide-membrane interactions to specific membrane components [51]. 
Moreover, giant plasma membrane vesicles (GPMVs) also provide a highly attractive 
system, since their membranes retain the molecular richness with lipids, proteins and 
extracellular matrix constituents of the cell membrane which they derived from [156]. Thus, 
using this system, it is possible to assess the peptide-membrane interactions in a 
biologically complex and highly relevant environment [134].  
However, to unravel the factors which are mandatory for efficient cellular translocation and 
moreover drug delivery, it is important to study and characterize the interplay of CPPs and 
membrane components in detail. Therefore, several approaches were necessary and 
needed to be addressed, such as secondary structure, the influence of specific lipids as 
well as the binding affinity and membrane integrity. For this purpose, different biophysical 
methods, model systems and experiments were required owing to the fact that one single 
method is not sufficient in creating an overall picture about the elementary processes 
involved in the translocation of CPPs across lipid membranes.  
Herein, the focus lied on different experimental approaches using artificial model membrane 
systems to assess in detail the interactions of CPPs, developed in our working group, with 
several lipid compositions, as well as the impact on membrane integrity. Moreover, 
structural changes of CPPs in a membrane mimetic environment became another subject 
of interest.  
Therefore, several methodological techniques were established, which will be examined 
more precisely in the following.  
Studying peptide-membrane interactions  
The interaction of cell-penetrating peptides with model lipid membranes has been studied 
using fluorescence approaches including confocal laser scanning microscopy (CLSM) and 
flow cytometric analysis.  
Giant unilamellar vesicles were used for microscopic analysis due to their large size 
facilitating microscopic observation, in contrary, large unilamellar vesicles were employed 
for flow cytometric binding studies. The phospholipids, sterols and sphingomyelin chosen 
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for the lipid compositions mimic those components of mammalian plasma membranes. At 
the same time, the system was tried to keep as simple as possible allowing to find specific 
answers concerning the elementary principles of peptide-membrane interactions and thus 
translocation mechanism. 
So far, a large body of literature exists that already reported on the use of giant unilamellar 
vesicles to investigate peptide-lipid interactions using CLSM [83, 91, 200]. Herein, GUVs 
were prepared by gentle hydration method provided by Horger et al., which includes the 
formation hybrid film of partially dried agarose and lipids (Figure 13) [76]. 
 
Figure 13. Formation of giant unilamellar vesicles by using the method of Horger et al., 2009. GUVs containing different 
lipid compositions were generated (see figure right). (modified after Horger et al., 2009 [76]) 
Hydrating the films of agarose and lipids under ionic conditions close to physical ones 
resulted in swelling and partial dissolution of the hybrid films and subsequently in rapid 
formation of giant unilamellar vesicles in high yield and large size (up to 100 µm) [76]. The 
great advantage over conventional procedures is the fact that this method did not require 
the presence of an electric field [10], a separate prehydration step [147] or specific lipids 
[3].  
To allow the observation of peptide-GUVs membrane interactions with fluorescence 
techniques, lipid compositions were doped with a fluorescent probe prior to vesicle 
formation and 5(6)-carboxyfluorescein labeling was used to detect peptides (Figure 14B 
and C). Moreover, GUVs can be prepared featuring coexisting liquid-disordered (Ld) and -
ordered (Lo) lipid phases using specific lipids and markers to visualize the phase separation 
(Figure 14A).  
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Figure 14. Fluorescence microscopic images of giant unilamellar vesicles (GUVs). GUVs composed of 
DOPC/DOPG/SM/Chol doped with DiI in order to visualize the Ld phases (A). The microscopic image in (B) shows in red the 
labeled vesicle membrane with Atto550-DOPE and in blue the entrapped dye allowing to investigate membrane destabilizing 
effects of peptides. CLSM analysis of GUVs treated with CF-labeled Transportan and (sC18)2 (C). Scale bars, 30 µm. 
In general, the experimental set-up enables us to gather selective information about the 
interaction loci of CPPs at the membrane of GUVs and specific membrane components 
required for an efficient interaction. Moreover, the direct visualization and quantitative 
analysis of pore forming events in model membranes will be possible [194]. For example, 
the upper microscopic image in Figure 14C shows the preferential accumulation of CF-
labeled well-described CPP Transportan on the Ld phase of GUVs featuring Lo and Ld (red 
membrane label) domains. The lower image displays the strong accumulation of the dimeric 
sC18 peptide on negatively charged GUV membranes which is accompanied by a nearly 
complete release of the blue dye (Oyster 405). These results show that both cell-penetrating 
peptides bind with a strong affinity to the vesicle membranes which leads to noticeable 
membrane perturbations. Thus, experimental conditions, such as peptide concentration, 
membrane lipid composition, and charge of the lipids, are important factors which have to 
be considered [111]. 
Recently, a new flow cytometric assay was developed to quantify interactions between 
proteins and membrane lipids [180]. In particular, this system offers the opportunity to 
quantify the binding affinity of peptides to membrane lipids reconstituted in large unilamellar 
vesicles and moreover peptide-induced changes in membrane curvature and tethering in a 
rapid and efficient manner [180]. Furthermore, only small amounts of peptide and lipids are 
needed, making this method attractive. However, to detect peptide-lipid membrane 
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interactions using this technique, LUVs and peptides have to be labeled with a fluorescent 
marker [180]. Nevertheless, with this potent flow cytometric based assay in hand, essential 
binding affinities can be detected and quantified in an effective way (as mentioned in Section 
4.1.2). Figure 15 illustrates the simplified work flow of such an experiment, also used in this 
thesis, in order to obtain more quantitative data about the accumulation of fluorescent 
labeled CPPs in vesicle membranes. 
 
Figure 15. Schematic overview of the binding and penetration affinity of CPPs towards large unilamellar vesicles 
(LUVs). Both, LUVs and CF-CPPs are added to a 1.5 ml tube and incubated for 2 h while slowly shaken. The quantification 
of CF-labeled CPPs into LUVs is then determined by flow cytometry. 
Lately, the use of giant plasma membrane vesicles as model membranes has received 
more attention to investigate interactions of peptides with components of membranes [7, 
106, 156, 162]. Furthermore, the study by Säälik et al. revealed that the membranes of 
GPMVs segregate into liquid-ordered and liquid-disordered phases and could further 
demonstrate by confocal laser scanning microscopy that amphipathic CPPs (such as 
Transportan) preferentially interact with Ld membrane domains [156]. The experimental set-
up and results of such an experiment are depicted in Figure 16. 
 
Figure 16. Illustrative overview ranging from the preparation of giant plasma membrane vesicles, the experimental 
set-up, as well as the interpretation of the results. (adapted from Säälik et al., 2014 [156])  
This kind of model membrane allows to identify other membrane components of plasma 
membranes, which are required for an efficient uptake. Moreover, using giant plasma-
Results and Discussion 
 
39 
derived vesicles, Amand et al. could demonstrate a linear correlation between GPMV 
binding and cellular internalization suggesting that internalization can be directly linked to 
the amount of peptide bound to the cell surface [7]. In this study, this technique was applied 
too.  
Studying peptide-induced membrane destabilization effects  
The ability to cause membrane perturbation seems to be a prerequisite for CPPs that are 
able to directly translocate across the cell membrane in an energy-independent manner. 
Thus, membrane destabilization effects appeared to play an important role in efficient 
uptake [51]. 
A common way to quantify the extent of membrane destabilization caused by peptides is 
via its capability to induce leakage of vesicle-entrapped fluorescent probes [48]. Within this 
work, 5(6)-carboxyfluorescein (CF) was included into large unilamellar vesicles. However, 
also the inclusion of calcein is often reported and both fluorophores are then used at a 
concentration that causes self-quenching [113]. Upon disruption of the membrane caused 
by peptides, the self-quenched fluorophore is released from the LUVs and generates strong 
fluorescence signals, which can be monitored using a plate reader [113]. Figure 17 
represents a schematic overview of such a CPP-induced CF-leakage experiment that was 
established during this work.  
 
Figure 17. Schematic sketch of CPP-induced CF-release experiment. Cell-penetrating peptide was added to LUVs 
encapsulating high concentration of membrane-impermeant fluorophore CF. The fluorescence intensity in the presence of 
100 mM CF is low due to self-quenching but increases upon CF release and therefore dilution in the outside medium. 
The application of such dye releasing experiments can provide insight into possible pore 
forming events and thus into the mode of action [68]. Moreover, increased membrane 
permeability is also often related to toxicity of peptides [51, 157].  
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Studying secondary structure of CPPs upon membrane binding 
Circular dichroism (CD) spectroscopy is often used to investigate peptide conformational 
changes upon association with model lipid membranes. For this purpose, large unilamellar 
vesicles (LUVs) are appropriate due to their size and smaller curvature [51]. In general, CD 
spectroscopy relies on the fact that optically active molecules (e.g. peptides) have different 
absorption of right- and left-polarized light [51, 113]. Thus, CD spectra of peptides, which 
are typically recorded in the far-UV region (250 – 180 nm) corresponding to peptide bond 
absorption, can be analyzed for the different secondary structural types, such as α-helix 
and β-sheet [92].  
So far, several studies exist that have investigated the secondary structure of peptides in 
presence of model membranes to identify whether their tendency to adopt a secondary 
structure in a membrane mimetic environment correlates to their internalization capacities 
[87, 114]. However, for the first time, such experiments were performed for sC18 variants. 
4.1.2 Impact of branched and cyclic CPPs on model membranes  
In this chapter, the interactions of two structurally modified variants of the sC18 peptide with 
several bilayer models were studied, with the goal to contribute to the mechanistic 
understanding of peptide-membrane interactions as a step towards cellular internalization. 
Moreover, one aim was to identify components of the plasma membrane that govern the 
initial step of cell entry. Therefore, the four methodological approaches, as mentioned 
above, were employed to shed light on urgent features, which are necessary to identify 
CPPs as superior delivery vehicles. 
Lately, the cell-penetrating peptide sC18, the cationic C-terminal fragment of the 
antimicrobial protein CAP18, was structurally modified by our working group to improve its 
efficiency as cell-penetrating peptide. Consequently, two strategies have been exploited, 
including the dimerization of sC18 resulting in a branched peptide structure [78], and the 
cyclization of the peptide backbone by click chemistry [77] in order to improve cellular 
uptake and drug delivery.  
Table 9 summarizes in detail some characteristic facts about the branched and cyclic 
variants of the sC18 peptide used in this chapter. 
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Table 9. Names, sequences and analytical data of peptides. All peptides are amidated at the C-terminus and additionally labeled with 5(6)-carboxyfluorescein.  
Peptide Sequence MWcalc. [Da] MWexp. [Da] Yield [%] Net charge 
sC18 GLRKRLRKFRNKIKEK 2069.60 2070.47 36 +9 
sC18* GLRKRLRKFRNK 1570.96 1571.44 29 +8 
(sC18)2a 
                              GLRKRLRKFRNKIKEK 
   GLRKRLRKFRNKIKEK 
4122.16 4122.44 22 +17 
lin(sC18)2a GLRKRLRKFRNKIKEKGLRKRLRKFRNKIKEK 4122.16 4122.05 38 +17 
(sC18*)2b 
                      GLRKRLRKFRNK 
   GLRKRLRKFRNK 
3124.91 3125.04 43 +15 
lin(sC18*)2a GLRKRLRKFRNKGLRKRLRKFRNK 3124.91 3126.15 44 +15 
cyc1c BLRXRLRKFRNK 1635.01 1634.78 26 +7 
cyc2c BLRKRLRXFRNK 1635.01 1634.89 30 +7 
cyc3c BLRKRLRKFRNX 1635.01 1634.66 30 +7 
B: L-propargylglycine, X: L-(Ɛ-azido)-lysine; ___: amino acids involved in cyclization; a provided by Gronewold, A.; b provided by Natividad-Tietz, S.; c provided by Reichart, F. 
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Branched peptides 
Peptide-membrane interactions play an essential role in the selective targeting of peptides 
to specific types of cells and tissues, since the membrane composition of both several 
organisms and cell compartments can be very different [60].  
Hence, mammalian cell membranes are composed mostly of glycerol-based phospholipids, 
like phosphatidylcholine and phosphatidylethanolamine as zwitterionic lipids and 
phosphatidylserine and phosphatidylinositol as anionic lipids, sphingolipids and cholesterol 
[37, 204]. Beyond that, anionic phospholipids are usually only present in the inner leaflets 
of plasma membranes [37]. However, several studies have reported on a change in tumor 
cells membrane composition, which resulted in more anionic nature due to the enrichment 
of negatively charged lipids (like phosphatidylserine) in the outer leaflet of the plasma 
membrane [85, 188].  
Previously, a study by Hoyer et al. demonstrated that the dimerization of sC18, namely 
(sC18)2, led to an enhancement of the cellular uptake efficiency, which was particularly 
accompanied by a certain selectivity towards tumoral cells [78]. These results are in close 
agreement with those obtained recently by Gronewold et al. based on further intense cell 
selectivity studies [68], and moreover unveiled (sC18)2 as promising carrier of the 
anticancer drug actinomycin D over its linear monomeric counterpart sC18 [68].  
Herein, the main focus was laid on understanding the relevance of membrane compositions 
with respect to membrane interaction and integrity of the dimeric CPP (sC18)2 in presence 
of membrane mimetic systems. Moreover, the influence of branching was further 
investigated, and therefore, several versions of the cell-penetrating peptide sC18 were 
designed and synthesized by our working group summarized in Table 9. Besides sC18, a 
truncated version of sC18, namely sC18*, missing four amino acids form the C-terminal part 
(inclusive glutamic acid) was chosen that still showed sufficient cell-penetrating properties 
[77]. Besides, the corresponding helical wheel plot highlighted the segregation of two 
distinct hydrophilic and hydrophobic faces resulting in a balanced ratio which was assumed 
to be essential for optimal peptide-membrane interactions [77]. Furthermore, to investigate 
the importance of branching for CPPs activity, both the branched dimeric versions of sC18 
and sC18* and their linear counterparts, lin(sC18)2 and lin(sC18*)2, were selected. 
So far, it was already shown that the internalization efficiency in several cell lines of the 
branched dimeric peptide (sC18)2 is vastly superior compared to the monomeric version 
sC18 [68, 78]. In particular, (sC18)2 internalized to a much higher extent into the cancer cell 
line MCF-7 than into the non-cancer cell line HEK-293, which was further investigated by 
an extensive uptake screening on various cell lines supporting the idea of tumor cell 
selectivity [68]. Moreover, the mechanism of cell entry was shown to be energy-dependent 
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in HEK-293 cells, whereas (sC18)2 was evenly distributed throughout the cytosol and in the 
nucleus in MCF-7 cells, clearly indicating that a large fraction of (sC18)2 was internalized 
via direct penetration and by endocytosis followed by improved endosomal escape [68].  
Additionally, the influence of branching on internalization efficiency and cytotoxicity was 
investigated using the linear version of (sC18)2, revealing a strong internalization capacity 
similar to (sC18)2 but also a tendency to a slightly higher cytotoxic profile [68]. However, 
regardless of branched or linear, the reason for the improved uptake efficacy of the dimeric 
sC18 conjugates is obviously attributed to the enhancement of the positive charges within 
in the peptide sequence resulting in increased peptide-membrane interactions essential for 
efficient uptake [68, 78]. In this context, initial insights on the relevance of membrane 
compositions were already obtained using large and giant unilamellar vesicles concerning 
the monomeric version and the branched dimer (sC18)2. However, within this part, the focus 
will be on the branched and linear dimeric sC18 variants. 
The influence of an anionic lipid on peptide-membrane interactions 
First, the membrane interaction and destabilization activity of the peptide conjugates were 
investigated using neutral (DOPC/DOPE) and negatively charged lipid 
(DOPC/DOPE/DOPG) model systems as representatives of non-cancer and cancer cells, 
respectively. To allow microscopic analysis, membranes of giant unilamellar vesicles 
(GUVs) were prior doped with 0.2 mol% Atto550-DOPE (red fluorescent dye). In addition, 
to evaluate the peptide effect on membrane perturbation, GUVs encapsulating a 
membrane-impermeant blue fluorescent dye Oyster 405 were prepared.  
Subsequently, the interaction of CF-labeled peptides with both giant unilamellar vesicle 
compositions were studied by confocal laser scanning microscopy (CLSM) depicted in 
Figure 18.  
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Figure 18. The influence of the negatively charged lipid phosphatidylglycerol (DOPG) on the interaction with model 
membranes. Microscopic analysis of GUVs composed of DOPC/DOPE (50:50) and DOPC/DOPE/DOPG (40:30:30) treated 
with various sC18 conjugates (10 µM) for 30 min and analyzed by CLSM. All GUVs contain 0.2 mol% Atto550-DOPE as lipid 
marker and were additionally loaded with 5 µM of the blue fluorescent dye Oyster 405. Scale bars, 30 µm. 
As shown in the left panels of Figure 18, no significant accumulation of CF-labeled peptide 
conjugates was observed on the membranes of neutral GUVs when incubating them with 
10 µM peptide solution for 30 min. In contrast, in the presence of anionic lipids (DOPG), 
peptide treatment resulted in strong green fluorescent signals on the membranes (right 
panels, Figure 18), which is not surprising since the preferential accumulation of Arg-rich 
peptides on negatively charged membranes was previously described by several studies 
[35, 181, 210]. Moreover, these results are in close consistency with former findings for 
sC18 and (sC18)2 obtained by Gronewold et al. [68].  
To gain a deeper insight into the membrane accumulation of peptide conjugates with giant 
unilamellar vesicles, GUVs were loaded with a fluorescent dye as mentioned above and the 
efflux of dye was assessed by fluorescence microscopy. The quantitative evaluation is 
represented in Figure 19A. Additionally, 5(6)-carboxyfluorescein leakage experiments were 
performed using large unilamellar vesicles (LUVs) of the same lipid compositions as GUVs 
and loaded with CF to investigate whether peptides perturbed vesicle membrane integrity 
(e.g. via pore formation) shown in Figure 19B. 
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Figure 19. Peptide-induced leakage from DOPC/DOPE (50:50) and DOPC/DOPE/DOPG (40:30:30) model membranes 
treated with sC18 conjugates. The relative fluorescence intensities of the enclosed Oyster 405 dye in DOPC/DOPE (50:50) 
and DOPC/DOPE/DOPG (40:30:30) GUVs after incubation with 10 µM CF-labeled sC18 variants for 30 min (A). As control, 
untreated GUVs were used. Means ± standard deviation (s. d.) of more than 10 GUVs are shown. CF release from neutral 
and anionic LUVs over time after peptide addition (1 µM) (B). The results of CF-release experiments are representative of 
three independent preparations of LUVs. Experiments were conducted in duplicate with n = 2. 
Judged from microscopical observation, no noticeable decrease in Oyster 405 signal was 
observed using neutral vesicles which could be further confirmed by CF-leakage 
experiments revealing no peptide-induced CF release (left panels, Figure 19A and B). 
Meaning that the membrane integrity was not affected by addition of peptide conjugates. 
However, in case of negatively charged model membranes, the effect of both linear and 
branched dimeric sC18 conjugates was remarkable compared to the parent monomeric 
versions (right panels, Figure 19A and B). Thus, the leakage rate was strikingly higher which 
was more obvious for CF-release experiments (right panel, Figure 19B). Here, the peptides 
led to a very fast leakage of CF that occurred in a matter of few minutes and saturated after 
about 1 h, indicating strong interactions with anionic membranes, which presumably 
triggered pore formation events. Meanwhile, the monomeric control peptides caused only 
negligible (below 10%) CF release, although the peptides bound to anionic membranes. 
However, these results suggest that the dimeric peptides significantly perturbed the 
membrane integrity in the presence of anionic lipids (DOPG) accompanied by strong 
membrane accumulations, which agree with microscopic observations and moreover with 
the literature [68, 77, 86]. Furthermore, since the peptide conjugates were not able to 
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interact with neutral model membranes, our data corroborates further the importance of 
negatively charged components at the outer leaflet of plasma membranes. 
The impact of membrane fluidity on peptide-membrane interactions 
In a next step, sphingomyelin (SM) and cholesterol (Chol) were introduced to a negatively 
charged lipid composition (DOPC/DOPG). This was done not only because mammalian 
plasma membranes consist of these, but also to elucidate the effect of membrane fluidity 
on peptides interaction loci within the membrane, since the addition of SM and Chol resulted 
in a more tightly packed, cholesterol and sphingomyelin-rich liquid-ordered phase (Lo), also 
referred to as lipid rafts [49].  
Therefore, DOPC/DOPG/SM/Chol (20:20:40:20) GUVs containing Oyster 405 were 
prepared and treated with 10 µM CF-labeled peptide conjugates for 30 min followed by the 
assessment of peptide accumulation using fluorescence microscopy. To visualize the effect 
of phase separation on peptide-membrane interaction, 0.2 mol% DiI, a dye that has been 
reported to distribute preferentially into the loosely packed, more dynamic liquid-disordered 
(Ld) lipid phase [15], was incorporated. 
 
Figure 20. CLSM analysis of GUVs composed of DOPC/DOPG/SM/Chol (25:5:50:20) treated with sC18 conjugates. 
GUVs loaded with Oyster 405 were incubated with 5(6)-carboxyfluorescein labeled sC18 conjugates (10 µM) for 30 min and 
analyzed by fluorescence microscopy. 5(6)-carboxyfluorescein labeled peptide (green) and Oyster405 dye (blue). All GUVs 
contain 0.2 mol% DiI as Ld phase marker (red), which was also regarded as lipid marker in this experiment. Scale bars, 30 µm. 
As shown in red channels of Figure 20, DOPC/DOPG/SM/Chol vesicles revealed distinct 
phase separations, which become more evident focusing on the GUV surface. Thus, the 
black areas within the membrane represent the more tightly packed, cholesterol and 
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sphingomyelin-rich liquid-ordered phase, while the more dynamic Ld phase is labeled by 
incorporation of the DiI dye (red areas in Figure 20).  
Interestingly, under the conditions used in this experiment, the monomeric peptides did not 
accumulate on the membranes, while the addition of dimeric versions resulted in strong 
peptide signals, which were not homogenously distributed along the membranes. In 
particular, the green fluorescence of the linear dimers seemed to co-localize well with those 
of the DiI dye suggesting that these peptides preferentially interact with membrane domains 
of a more dynamic and less densely packed nature. These results are indeed in line with 
previous reports revealing the preference for membrane-affine CPPs with liquid-disordered 
phases [156, 209]. However, for (sC18)2 and (sC18*)2, no obvious phase preference could 
be found. Instead, the peptide signal was unevenly distributed on both Lo- and Ld phases. 
Nevertheless, the overall higher membrane affinity of the dimeric conjugates might be 
related, on the one hand, to the enhanced amphipathic properties of dimeric conjugates 
compared to the monomeric ones [210]. The linear dimers in particular adopt a nearly 
perfect α-helical structure separating charged and non-charged residues into an 
amphipathic structure, which might be accountable for the increased membrane affinity [68]. 
On the other hand, several studies have suggested that the presence of at least six arginine 
residues in the structure is necessary for efficient cellular uptake [59, 133, 198].  
 
Figure 21. Peptide-induced leakage from DOPC/DOPG/SM/Chol (25:5:50:20) model membranes treated with sC18 
conjugates. The relative fluorescence intensities of the enclosed Oyster 405 dye in DOPC/DOPG/SM/Chol (25:5:20:20) 
GUVs after incubation of 30 min with 10 µM CF-labeled sC18 variants (A). As control, untreated GUVs were used. Means ± 
standard deviation (s. d.) of more than 10 GUVs are shown. CF release from LUVs mimicking mammalian plasma membrane 
over time after peptide addition (1 µM) (B). The results of CF-release experiments are representative of three independent 
preparations of LUVs. Experiments were conducted in duplicate with n = 2. 
Focused further on the encapsulated fluorescent dye within the GUVs (Figure 21A), no 
dramatic decrease in Oyster 405 signal was observed for all peptides, despite peptide 
binding. Similar results were obtained when CF-entrapped LUVs were treated with peptide 
conjugates for 60 min indicating that in the presence of SM and Chol, the membrane 
destabilization effect of peptides, as observed for anionic model systems, was significantly 
impaired. In this context, a previous study by Katayama et al. demonstrated that the addition 
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of cholesterol in GUV membranes prevented the leakage of an encapsulated fluorescent 
dye [91]. Moreover, Säälik et al. reported on an increase in penetration efficiency of CPPs 
of different subclasses into cholesterol-depleted giant plasma membrane vesicles. This 
provoked the assumption that since Chol has been demonstrated to be crucial for the 
formation of the Lo phase [49, 168], it could indeed hinder the internalization of CPPs and 
therefore the efflux of an entrapped dye [156]. Thus, this could be an explanation that no 
significant release of the GUV and LUV-encapsulated fluorescent dye could be observed 
(Figure 21).  
However, as a result of this observation, it was questioned whether Chol is indeed 
responsible for the impaired leakage rate or whether the presence of the so-called lipid raft 
domain in general is accountable. Therefore, this purpose was researched in greater detail 
by preparing GUVs and LUVs composed of DOPC/DOPE/DOPG, which were additionally 
supplemented either with Chol or SM, and the membrane interaction and integrity was 
assessed by fluorescence microscopy (Figure 22) and spectroscopy (Figure 23).  
 
Figure 22. The influence of cholesterol and sphingomyelin on the interaction with model membranes. Microscopic 
analysis of GUVs composed of DOPC/DOPE/DOPG/Chol (37.5:37.5:5:20) and DOPC/DOPE/DOPG/SM (22.5:22.5:5:50) 
treated with various sC18 conjugates (10 µM) for 30 min and analyzed by CLSM. All GUVs contain 0.2 mol% Atto550-DOPE 
as lipid marker and were additionally loaded with 5 µM of the blue fluorescent dye Oyster 405. Scale bars, 30 µm. 
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As shown in the left panels of Figure 22, all peptides bound with a strong affinity to GUV 
membranes supplemented with Chol which was surprising, since these observations differ 
from that reported by others [91, 156]. Furthermore, only minor Oyster 405 signals remained 
inside the GUVs after 30 min of peptide incubation indicating remarkable impacts of peptide 
conjugates on the membrane integrity, presumably through pore forming events. As 
comparison, while adding SM to DOPC/DOPE/DOPG vesicles, no accumulation along the 
membrane could be revealed which was accompanied by no Oyster 405 escape (right 
panels in Figure 22).  
 
Figure 23. The impact of cholesterol and sphingomyelin on the membrane perturbation activity of sC18 conjugates. 
CF-leakage experiments from LUVs composed of DOPC/DOPE/DOPG/Chol (37.5:37.5:5:20) (A) and 
DOPC/DOPE/DOPG/SM (22.5:22.5:5:50) (B). Peptides (1 µM) were added to LUVs and the release of CF from vesicles was 
monitored by measuring the increase in fluorescence intensity. At the end of each experiment, Triton X-100 (0.4% (w/v) final 
concentration) was applied to measure the maximum of dequenching that was used to normalize data. Experiments were 
conducted in duplicate with n = 2. 
Furthermore, a detailed analysis of the influence of Chol and SM on the membrane 
perturbation activity of these peptides revealed a rapid and complete CF release when Chol 
LUVs were treated with 1 µM peptide conjugate over a time of 60 min (Figure 23A). While 
the peptides could not disrupt the membrane in the presence of SM and thus, no CF release 
from the vesicles could be observed (Figure 23B). 
However, the anionic phospholipid DOPG was added only in small amounts (5 mol%) and 
therefore cannot be responsible for the strong membrane affinity in 
DOPC/DOPE/DOPG/Chol GUVs and LUVs. Rather, it is assumed that the presence of Chol 
in the membrane of liposomes contributes to the increased membrane affinity which is 
accompanied by lytic membrane activity. Interestingly, the presence of SM alone had no 
impact on membrane interaction and integrity which is in consistence with a previous study 
by Wallbrecher et al. Here, it was reported that the translocation of the well-known CPPs 
R9 (nona-agrinine) and penetratin into POPC/POPG/Chol GUVs either supplemented with 
SM or not were not dependent on the presence of SM [195]. Nevertheless, the data let 
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conclude that in the presence of both membrane components in the vesicles, peptides 
membrane disruption activity is hampered.  
However, considering Chols importance in the formation of Lo domains and in endocytosis 
and the fact that endocytotic pathway was found to play a dominant role in sC18 and (sC18)2 
uptake in HEK-293 cells and to some extent in MCF-7 cells, the next experiments focused 
on the effect of cholesterol on translocation.  
Cholesterol and its effect on peptides cellular uptake efficacy  
We looked into the role of Lo domains on CPP internalization in living cells by abolish the 
formation of lipid rafts. A simple method to avoid these Lo phases is provided by the removal 
of cholesterol using methyl-β-cyclodextrin (MβCD) [17, 72]. Thus, cholesterol depletion 
assays were performed, monitored by fluorescence microscopy and finally quantified by 
flow cytometry (Figure 24).  
 
Figure 24. The influence of cholesterol extraction by cyclodextrin treatment on internalization efficiency. MCF-7 and 
HEK-293 cells were treated with 10 mM methyl-β-cyclodextrin (MβCD) for 1 h and subsequently incubated with 5 µM CF-
sC18 or 1 µM CF-(sC18)2 for 30 min at 37 °C. Microscopic analysis of peptide internalization is shown in (A). The peptide is 
labeled in green and the cell nuclei stained in blue. Scale bars, 10 µm. Quantification by flow cytometry is presented in (B). 
Experiments were performed in triplicate with n = 3.  
Herein, the main emphasis is on the branched dimeric version (sC18)2 and the monomeric 
sC18 control peptide using HEK-293 and MCF-7 cells, respectively. Unfortunately, the 
experimental set-up for microscopic analysis of HEK-293 cells failed. Consequently, we 
obtained data only from the quantitative evaluation by flow cytometry.  
However, a significant effect of cholesterol extraction on the internalization of sC18 could 
not be revealed in both the non-cancer cell line and cancer cell line (Figure 24A and B), 
indicating that cellular uptake and subcellular distribution was not affected. These results 
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are a bit controversial, since strong membrane interactions with GUVS and LUVs composed 
of DOPC/DOPE/DOPG/Chol could be observed which were accompanied by peptide-
induced CF-leakage. In contrast, MβCD treatment in both HEK-293 and MCF-7 cells 
reduced the internalization capability of (sC18)2 dramatically and moreover the cytoplasmic 
fluorescence. As shown in Figure 24A, the peptide was still marginal localized within the 
nucleus, while no peptide signal was found in the cytosol of MCF-7 cells. From these 
findings, it was suggested that the uptake of (sC18)2 may also involve the lipid raft-
dependent endocytosis, besides direct translocation, since cholesterol depletion is also a 
method to inhibit this type of endocytotic uptake [16]. Accordingly, the exact pathway of 
endocytosis used by sC18 could not be identified.  
However, the interplay of all these results might indicate that efficient translocation of these 
cationic peptide conjugates relies on the presence of anionic lipids, such as DOPG, and 
moreover on the presence of membrane domains with high fluidity, which also appears 
mandatory for the uptake to occur. Furthermore, in case of the parent control peptide, Chol 
depletion by MβCD treatment revealed no impact on its internalization capability, while the 
uptake of the branched dimer (sC18)2 was significantly hampered which lets one assume 
that the dimeric peptide translocates across the membrane via lipid raft-dependent 
endocytosis. Since peptide signals in the nucleus were still observed (Figure 24A), which 
indicates a pathway via direct translocation, these results suggest that the (sC18)2 peptide 
is internalized by more than one mechanism depending on the composition of the target 
cell membrane. 
The role of other membrane constituents in peptide-membrane interactions 
So far, some insights into the interplay of membrane composition and peptide-lipid 
interactions of branched and linear versions of the cell-penetrating peptide sC18 were 
provided. However, to go further into detail giant plasma membrane vesicles (GPMVs) were 
used, which provide a more natural membrane system than LUVs and GUVs, since their 
membrane composition resembles that of living cells [156, 162]. 
Therefore, the role of other membrane lipids or proteins in the translocation ability of the 
peptides was further explored. Here, I established a method of preparing GPMVs from 
biological cells, in particular from HEK-293 and MCF-7 cells, by chemically induced plasma 
membrane vesiculation, as already described by Scott, R.E. [162]. To monitor peptides 
interactions with GMPVs, DiI was selected to label the membranes, while 5(6)-
carboxyfluorescein was used to mark peptides as already mentioned. Then, GPMVs were 
incubated with all sC18 conjugates at 1 µM concentration for 1 h at RT followed by 
visualization through fluorescence microscopy illustrated in Figure 25. 
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Figure 25. Accumulation of CF-labeled sC18 conjugates into giant plasma membrane vesicles (GPMVs) prepared 
from both MCF-7 and HEK-293 cells by DTT/formaldehyde treatment. GPMVs were incubated with CF-labeled peptides 
(green) at 1 µM concentration for 1 h at RT. Membranes were labeled with DiI (red). Scale bars,10 µm. 
All peptides were found to internalize and accumulate into GPMVs irrespective of the cell 
line used. Especially, the branched and linear dimeric sC18* versions strongly interacted 
with the membrane of MCF-7 derived GPMVs, resulting in vesicle debris depicted in the 
lower panels of Figure 25A.  
However, the strong accumulation of the CF-labeled peptides into the lumen of GMPVs 
obtained from both MCF-7 and HEK-293 cells compared to GUVs might suggest that some 
membrane proteins embedded within the vesicle membrane could specifically increase the 
peptide uptake across the cell membrane, but this requires further investigations.  
Nonetheless, this data shed new lights on the relevance of membrane compositions for the 
internalization mechanism of these peptides and moreover allowed us to identify some 
membrane properties, which are mandatory for efficient translocation. 
Cyclic peptides 
By now, many publications exist demonstrating that structural modifications of cell-
penetrating peptides contributed positively to their cellular penetration features [115, 185, 
198]. In particular, the use of cyclized peptides becomes increasingly attractive as promising 
delivery vectors, since backbone rigidification of CPPs leads to improved cellular uptake 
and proteolytic stability over its linear and more flexible counterpart [77, 104, 133].  
Indeed, we showed recently that cyclization of the truncated version sC18*, which resulted 
in three cyclic peptide derivatives varying in ring size and thus in the number of arginines 
included, leads to improved cell-penetrating properties, concerning proteolytic stability and 
translocation activity (for sequences refer to Table 9 and Figure 26) [77]. In more detail, we 
assumed that the enhanced distance between the guanidinium groups in the large cycle 
(cyc3) through cyclization of the peptide backbone and further introduction of a triazole 
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bridge leads to the enhanced cellular uptake over the smaller cycles and the linear 
counterpart.  
Thus, our data are consistent with previous studies, which reported that increased rigidity 
and the static display of guanidinium groups enhances the membrane contact and thus 
cellular penetration [77, 104, 185, 199]. Moreover, a study by Traboulsi et al. suggests that 
higher uptake rates of cyclic peptides are correlated with the increasing number of arginine 
residues within the cycle [185]. Consequently, it is supposed that the arginine residues are 
crucial for efficient cellular uptake due to the role attributed to their ability to interact with 
negatively charged components of the plasma membrane, e.g. the polar headgroups of 
phospholipids or the sulfate groups of glycosaminoglycans [30, 53]. 
Hence, since the uptake of CPPs has been attributed to the ability to engage in electrostatic 
interactions with the negatively charged constituents of the plasma membrane, artificial 
membrane systems lacking energy-driven processes were employed to shed light on the 
molecular level of cyclic peptides cell entry.  
Therefore, based on the truncated version sC18*, three cyclic peptides (cyc1 – cyc3), that 
varied in ring size and thus in the number of arginine residues included, were designed and 
finally synthesized by our working group (Table 9 and Figure 26). To allow selective side-
chain cyclization via copper (I) mediated alkyne-azide click (CuAAC) chemistry, glycine and 
lysine were substituted by propargylglycine and aziodlysine, respectively. Furthermore, to 
address the impact of cyclization on peptide-membrane interactions, the corresponding 
linear counterpart sC18* was synthesized as control. 
 
Figure 26. Structures of cyclized peptides. Cyclization was achieved by the CuAAC reaction connecting residues 1 + 4 
(cyc1), 1 + 8 (cyc2) and 1 + 12 (cyc3) of the linear peptide (1GLRKRLRKFRNK12). 
So far, the uptake mechanism of these cyclic peptides was found to be energy-independent 
in cancer cells (MCF-7), while endocytosis was confirmed as main entry pathway in the non-
cancer cell line HEK-293, since the cellular efficiency was significantly diminished at 4 °C 
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[77]. Moreover, first insights into peptide/lipid interactions were already gathered using giant 
unilamellar vesicles (GUVs) as artificial membrane system. Our findings highlighted a 
considerably strong accumulation of the different sized cycles on anionic GUV membranes, 
which is interesting considering that the outer leaflet of cancer cells have been shown to be 
primary anionic [85].  
However, the secondary structure formation of CPPs might play a major role in stabilizing 
their interactions with membranes and thus promoting cellular uptake [50, 77]. Therefore, 
the ability of these peptides to adopt an ordered secondary structure, at least in a membrane 
mimetic environment, is indispensable.  
Structural characterization of cyclic peptides in the presence of vesicles 
For this purpose, circular dichroism spectroscopy was used to analyze the structural state 
of the cyclized peptides in the presence of neutral and negatively charged large unilamellar 
vesicles (LUVs).  
 
Figure 27. Circular dichroism spectra of 20 µM 5(6)-carboxyfluorescein labeled cyclic peptides (cyc1 – cyc3) and 
linear precursor peptide sC18* in 25 mM phosphate buffer, pH 7.4 and in presence of neutral and anionic LUVs at a 
P/L ratio of 1/50.  
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As shown in Figure 27, all peptides revealed an unstructured conformation in phosphate 
buffer. Despite it has been reported that cyclic peptides might be conformationally stabilized 
by a 1,4 disubstituted 1,2,3-triazole bridge [28, 77], the present observations did not match 
with any secondary structure motif. Nevertheless, similar results were obtained in the 
presence of neutral vesicles and thus, the secondary structures did not change noticeably. 
However, in the presence of anionic lipids, the peptides became more structured; 
particularly the small-sized cycle cyc1 and the linear version might be highly influenced 
when incubated with negatively charged LUVs. Therefore, our data suggest that only cyc1 
and the linear version underwent a conformational transition from a random coil to a well-
defined secondary structure. This is not surprising since the C-terminal linear part of cyc2 
consists of only four amino acids which are indeed not able to form an appropriate 
secondary structure and cyc3 consists of no linear part.  
However, since strong interactions of cyc3 with anionic GUV membranes were observed, 
but no secondary structural motif, it was assumed that at least the guanidinium groups are 
forced into maximally distant positions leading to a stabilizing effect and thus a better 
peptide-membrane interplay, which might help to improve membrane integration and finally 
penetration.  
Membrane binding affinity and perturbation activity of cyclic peptides in the presence 
of vesicles 
Therefore, taking a closer look, the membrane binding affinity and the membrane 
perturbation effect of the peptides were investigated using neutral and anionic large 
unilamellar vesicles (LUVs) shown in Figure 28. 
First, the focus was on the membrane binding affinity of CF-labeled cyclic peptides as well 
as sC18* examined by flow cytometric analysis (Figure 28A). 
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Figure 28. Binding affinities and peptides effect on membrane destabilization using neutral and anionic LUVs. Flow 
cytometric binding studies of CF-labeled peptides (10 µM) with neutral and anionic LUVs after 2 h of incubation (A). 
Experiments were conducted in duplicate with n = 3. Error bars represent the standard deviation. Time course of peptide-
induced (20 µM) CF release from neutral and anionic LUVs (B). The results of CF-release experiments are representative of 
three independent preparations of LUVs. 
Obviously, an overall stronger accumulation was detected when peptides were incubated 
with negatively charged LUVs contrary to neutral LUVs (Figure 28A), which correlates well 
with our findings on giant unilamellar vesicles. However, the overall measured fluorescence 
of the cyclic peptides was only moderate when compared to the linear version.  
To investigate the possibility whether the peptide/lipid interaction causes alterations of the 
membrane integrity, 5(6)-carboxyfluorescein release experiments were performed as 
shown in Figure 28B. Therefore, LUVs composed of DOPC, DOPE (1:1) and DOPC, DOPE 
and DOPG (4:3:3) were employed and incubated with peptides at a P/L ratio of 1/50. The 
extent of CF-leakage from the vesicles induced by peptides was assessed over 60 min by 
monitoring increased fluorescence from the released fluorophore. As indicated in Figure 
28B, none of the peptides caused release of the entrapped fluorophore from neutral LUVs 
which is consistent with their inability to interact with zwitterionic membranes as determined 
by flow cytometric binding studies (Figure 28A). Consequently, these data let conclude that 
interactions of the cationic peptides with neutral LUVs are weakened due to repulsion 
between the cationic peptides and positively charged head groups of DOPC and DOPE. 
This assumption is in accordance with Gopal et al., who reported on weakened interactions 
of positively charged peptides with vesicles mimicking eukaryotic membranes due to 
repulsion [64]. However, in presence of anionic lipids, all peptides caused fast and efficient 
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release of up to 40% of total CF after 60 min of incubation. Strikingly, even though the 
binding affinity of the linear peptide towards the negatively charged LUV membranes was 
dramatically increased, the membrane activity of cyc1 and cyc3 was still significantly higher 
compared to the linear counterpart, which might suggest different modes of actions or 
different behavior during the translocation process. Therefore, it is quite possible that the 
mechanism of non-endocytotic entry, as observed for cyclic peptides in cancer cells, is 
related to the ability to cause localized destabilization of the plasma membrane since the 
membrane perturbation effect of cyc1 and cyc3 was remarkable. 
The impact of PI(4,5)P2 on peptide binding 
Further mechanistic investigation was conducted to determine the influence of the 
negatively charged phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) on peptide binding. 
Although, PI(4,5)P2 is only a minor component of the plasma membrane, localized on the 
cytoplasmic leaflet, it plays a major role as crucial regulator of various cellular processes 
including cell signaling, cytoskeleton organization as well as protein and membrane 
trafficking [161, 179]. Since PI(4,5)P2 is also known to be essential for a number of steps 
along the endocytotic pathway [38, 177], it was further interesting to shed light on the 
mechanistic process of endocytosis considering that this mechanism was supposed to be 
the main pathway of cyclized peptides in non-cancer cells. 
Thus, LUVs composed of DOPC as neutral lipid additionally supplemented with different 
mol% of PI(4,5)P2, kindly provided by Marcel Zeitler (group member of working group of 
Prof. Dr. Walter Nickel, BZH Heidelberg), were employed to assess the binding affinity of 
cyclic conjugates using flow cytometric technique (Figure 29A). Furthermore, LUVs loaded 
with CF were used in order to address whether the cyclic CPPs could disrupt the membrane 
and thus causing the release of CF from the vesicles (Figure 29B).  
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Figure 29. The influence of PI(4,5)P2 on binding affinities and membrane destabilizing activity using large unilamellar 
vesicles. Flow cytometric binding studies of CF-labeled peptides (2.5 µM) after 2 h of incubation with neutral LUVs 
supplemented with 5 mol% and 10 mol% PI(4,5)P2, respectively. (A). Experiments were conducted in triplicate with n = 1. 
Time course of peptide-induced (1 µM) CF release from neutral LUVs and DOPC vesicles supplemented with 10 mol% 
PI(4,5)P2 (B). These experiments were performed in cooperation with working group of Prof. Dr. Walter Nickel, BZH 
Heidelberg.  
As shown in Figure 29A, especially the linear peptide demonstrated high binding affinity to 
LUV membranes composed of phosphatidylcholine (DOPC) and 5, or 10 mol% PI(4,5)P2, 
whereas cyc1-3 showed decreased levels of accumulation depending on their ring size 
small < large. Moreover, the membrane destabilizing effect of the linear counterpart was 
also more evident and thus, sC18* was able to induce a significant dye release from LUVs 
supplemented with 10 mol% PI(4,5)P2, which is in consistent with the strong membrane 
binding affinity (Figure 29A). On the contrary, the incubation with cyclic peptides resulted in 
15 – 25% CF release over a 30 min time period (Figure 29B). However, not one of the 
peptides caused a sufficient dye release in neutral LUVs, which is in good agreement with 
the results obtained with LUVs composed of DOPC and DOPE (Figure 28B). 
These results strongly suggest that the linear peptide binds tightly to PI(4,5)P2 which was 
accompanied by membrane perturbation, while the binding affinity of cyclic peptides is not 
that pronounced. However, since it is known that peptides behavior depends highly on the 
peptide concentration as well [111], the low peptide concentration used during the 
experiments should be taken into account. Nevertheless, all these observations further 
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provide evidence for different lipid/peptide interactions and peptide membrane integration 
depending on lipid composition and peptide used.  
Moreover, these findings might provide an indication that the linear peptide can escape from 
endosomes more efficient, since the binding affinity towards PI(4,5)P2 was shown to be 
noticeable. In contrast, the weak binding of cyclic peptides might be related to the 
preferential uptake route via direct translocation and therefore, the binding affinity towards 
PI(4,5)P2 was not that strong. However, to better understand the peptide structure-
membrane-binding relationship, further investigations are necessary. 
The influence of further membrane constituents on peptide-membrane interactions 
In a last experiment, further mechanistic studies using giant plasma membrane vesicles, 
representing a more natural membrane model, were performed to elucidate in more detail 
how cells plasma membrane constituents affect peptides cell entry in conditions lacking 
endocytosis. 
Therefore, giant plasma membrane vesicles made of HEK-293 and MCF-7 cells were 
investigated in presence of fluorescently labeled peptide variants using fluorescence 
microscopy (Figure 30).  
 
Figure 30. Accumulation of CF-labeled peptides into giant plasma membrane vesicles (GPMVs) prepared from both 
HEK-293 and MCF-7 cells by DTT/formaldehyde treatment. GPMVs were incubated with CF-labeled peptides (green) at 
1 µM concentration for 1 h at RT. Membranes were labeled with DiI (red). Scale bars, 10 µm. 
As shown in Figure 30, all peptides were found to efficiently interact with GPMV membranes 
and translocate into GPMVs. The intensity of the internalization activity increases in the 
order cyc1 < cyc2 < cyc3 = linear. However, no differences in the uptake profile could be 
observed when incubating the peptides with GPMVs obtained from either HEK-293 or 
MCF- 7 cells. Though, considering that an endocytic uptake route for cyclic peptides in 
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HEK-293 cells was proposed, these findings might provide an indication that other direct 
translocation pathways are used when intact machinery responsible for endocytosis is not 
working properly, since strong signals within the vesicles were detected.  
Finally, our results obtained from model membrane studies confirm on the one hand that 
the presence of negatively charged lipids such as DOPG or PI(4,5)P2 are indeed essential 
to trigger the peptide-membrane interaction of cationic CPPs [35, 181]. On the other hand, 
it has been suggested that the presence of the larger dipole moment provided by the triazole 
bridge positively influenced the membrane integrity of cyclic peptide and thus related to the 
stronger membrane activity observed in anionic LUVs. However, the different modes of lipid 
interaction of the peptides might further indicate different uptake mechanisms, which should 
be further investigated. 
Nevertheless, the great uptake efficiencies, accompanied by superior serum stability over 
the linear counterpart, non-cytotoxicity, and synthetic accessibility, renders particularly the 
large-sized cycle as a useful transporter for e.g. plasmid DNA [77].  
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4.2 Cell-penetrating peptide conjugate with wound healing promoting 
activity 
4.2.1 Design of peptides and peptide synthesis 
The aim of this part of the thesis was to synthesize chimeric peptide conjugates consisting 
of a wound healing promoting peptide sequence, namely Tylotoin, and a cell-penetrating 
peptide followed by elucidation of their structural characteristics and biological activity 
(Figure 31).  
 
Figure 31. Design of chimeric peptide conjugates. The cell-penetrating peptide sC18/sC18* is either conjugated to the C-
terminus or the N-terminus of Tylotoin.  
The cell-penetrating peptides used in this part were the sC18 peptide, derived from the C-
terminal domain of the cationic antimicrobial peptide CAP18 [130] and a truncated version 
lacking four amino acids from the C-terminal part [77], namely sC18* still showing cell-
penetrating properties. The CPP was then either fused to the C-terminus or N-terminus of 
Tylotoin, a short peptide identified from salamander skin of Tylototriton verrucosus (Figure 
31) [126]. 
Recently, this peptide was found by Mu et al. [126] to exert the ability to promote wound 
healing similar to the epidermal growth factor (EGF), a polypeptide playing an essential role 
in mammalian wound healing [67, 73]. Tylotoin has the capability to enhance both the 
migration and proliferation of fibroblasts, keratinocytes and vascular endothelial cells, 
resulting in accelerated re-epithelialization and granulation tissue formation in the wound 
site [126]. Moreover, Mu et al. showed that Tylotoin also promotes the release of 
transforming growth factor β1 and interleukin 6 (IL-6), which are essential key regulators in 
the wound healing process [126].  
The goal of this chapter was to combine both peptides and thus create a more efficient 
peptide conjugate with improved wound healing efficacy and uptake efficiency that can be 
easily synthesized by solid phase peptide synthesis techniques and might be in future used 
as potent topical agent in wound treatment.  
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Table 10. Names, sequences and analytical data of peptides. All peptides are amidated at the C-terminus and N-terminally labeled with 5(6)-carboxyfluorescein. 
Peptide Sequence Origin MWcalc. [Da] MWexp. [Da] Yield [%] Net charge 
sC18 GLRKRLRKFRNKIKEK 
Rabbit 
cathelicidin 
2069.6 2070.47 36 +9 
sC18* GLRKRLRKFRNK 
Rabbit 
cathelicidin 
1570.96 1571.44 29 +8 
Tylotoin KCVRQNNKRVCK 
Skin of 
salamanders 
1474.81 1474.55 66 +6 
rTylotoin RNCVKKNCRVKQ - 1474.81 1474.88 76 +6 
Tylotoin-sC18 KCVRQNNKRVCKGLRKRLRKFRNKIKEK synthetic 3527.33 3527.57 74 +14 
Tylotoin-sC18* KCVRQNNKRVCKGLRKRLRKFRNK synthetic 3028.71 3028.80 23 +13 
sC18-Tylotoin GLRKRLRKFRNKIKEKKCVRQNNKRVCK synthetic 3527.33 3528.40 46 +14 
sC18*-Tylotoin GLRKRLRKFRNKKCVRQNNKRVCK synthetic 3028.71 3029.39 56 +13 
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The peptides used in this part were synthesized by automated solid phase peptide synthesis 
following Fmoc/t-Bu-strategy. Peptide sequences and analytical characteristics are 
presented in Table 10. Additionally, all peptides were N-terminally labeled with the 
fluorophore 5(6)-carboxyfluorescein for later fluorescence studies. Peptides were obtained 
in high purity as analyzed by analytical RP-HPLC and their identity was confirmed by 
electrospray ionization mass spectrometry. An exemplary HPLC chromatogram and ESI-
MS spectrum of purified Tylotoin-sC18* is shown in Figure 32. 
Figure 32. Chromatogram and ESI-MS of purified Tylotoin-sC18* obtained after preparative HPLC. The gradient was 5 
– 55% acetonitrile in water (incl. 0.1% FA) over 15 min and the standard was subtracted. UV-chromatogram of Tylotoin-sC18* 
(A). The peptide elutes at a retention time of 5.81 min. The corresponding mass-to-charge ratios are depicted in ESI-MS 
spectrum (B). calculated molecular weight 3028.71 Da, charged molecular ions found; ([M+3H]3+ = 1010.26; 
[M+4H]4+ = 758.54; [M+5H]5+ = 606.96; [M+6H]6+ = 505.88; [M+7H]7+ = 444.80; [M+8H]8+ = 379.73). 
The UV-chromatogram (Figure 32A) shows a main peak at a retention time of 5.81 min and 
the respective charged molecular ions are depicted in the ESI-MS spectrum (Figure 32B). 
The ESI-MS spectrum shows the 3-fold to 8-fold charged molecular ions corresponding to 
the peptide mass of Tylotoin-sC18* (MWcalc. = 3028.71 Da). Thus, the mass-to-charge ratio 
(m/z) was found to be nearly identical to the theoretical m/z and the peptide was obtained 
in high purity as indicated in UV-chromatogram. 
Structural characteristics 
First, to get some insights into the structural arrangements of the chimeric peptide 
conjugates and the parent peptides, the secondary structure was determined using circular 
dichroism spectroscopy (Figure 33).  
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Figure 33. Structural characteristics of investigated peptides. CD spectra were acquired at a peptide concentration of 20 
µM in 10 mM phosphate buffer, pH 7.0 (A) and in the additional presence of 50% TFE (B). The percentage of the α-helix 
content was calculated from the ellipticity value at 222 nm using the following formula: (% α-helix = 
(([𝚯𝟐𝟐𝟐] − 𝟑𝟎𝟎𝟎) (−𝟑𝟔𝟎𝟎𝟎 − 𝟑𝟎𝟎𝟎))⁄ × 𝟏𝟎𝟎) [34, 146]. R-values represent the ratio between the molar ellipticity values at 
222 and 208 nm [117] and R = 1 defined as hallmark for a perfectly built α-helix [98]. (C) Helical wheel projections of Tyolotin-
sC18* and sC18*-Tylotoin predicted by HeliQuest (D). 
The peptides were dissolved in 10 mM phosphate buffer as well as in phosphate buffer 
supplemented with 50% trifluoroethanol (TFE) to promote a helical assembly [56] and to 
stabilize the secondary structure [153].  
All peptide conjugates as well as Tylotoin and a random sequence of Tylotoin alone display 
a spectrum typical of an unordered conformation in 10 mM phosphate buffer, pH 7.0 (Figure 
33A), with minima around 197 nm – 200 nm. With the addition of TFE, the CD spectra 
revealed that all chimeric peptide conjugates become structured in α-helix conformations, 
whereas Tylotoin and rTylotoin are still in an unstructured form, respectively (Figure 33B). 
Previously, it was already shown that both sC18 [130] and sC18* [77] adopt an α-helical 
structure in the helix-inducing environment of TFE and thus, it was assumed that the 
attachment of the cell-penetrating peptide to Tylotoin supports the transition to helical 
structures. This was further supported after calculating the percentage of the α-helical 
content as well as the ratio between the molar ellipticity at 222 nm and 208 nm (R-value), 
where it is known that α-helical peptides have R-values of approximately 1 [117]. As seen 
from Figure 33C, both the α-helical content and the R-values were significantly increased 
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for the chimeric peptide conjugates in the presence of 50% TFE when compared with 
Tylotoin/rTylotoin alone. Moreover, the percentage of the α-helical content is slightly greater 
when CPP is fused to the C-terminus of Tylotoin. Therefore, a closer look at the helical 
wheel plot was taken, representing three-dimensional projection of amino acids within the 
α-helical structure [160]. A representative helical wheel plot for Tylotoin-sC18* and sC18*-
Tylotoin is depicted in Figure 33D, respectively. The helical wheel projection of Tylotoin-
sC18* highlighted two separate faces, one hydrophilic and one hydrophobic (VVLF). In 
contrast, the helical wheel plot of sC18*-Tylotoin showed no obvious differentiation into 
distinct domains. Thus, it was hypothesized that fusion of CPP to the C-terminal part of 
Tylotoin leads to a better hydrophobic/hydrophilic balance allowing optimal interaction of 
the peptide conjugates with the amphiphilic nature of biological membranes. 
4.2.2 Cytotoxicity against keratinocytes and cancer cells 
Next, the influence of the synthesized peptides on cell viability towards mammalian cells 
was investigated using a human skin and a cancer cell line. As representative cell line for 
skin cells, the human immortalized keratinocytes HaCaT were used. Keratinocytes are 
known to be an essential key cellular component of the epidermis involved in skin wound 
healing [136, 166, 201, 208]. Therefore, in order to use the peptides as potential wound 
healing agents, it is mandatory that the peptides exhibited no cytotoxic effects against 
human skin keratinocytes. Additionally, HeLa cells as representative cancer cell line were 
used to evaluate possible cytotoxic effects against tumor cells. 
Therefore, both cell lines were exposed to chimeric peptide conjugates at certain 
concentrations, ranging from 10 to 100 µM. As controls, both sC18 and sC18* as well as 
Tylotoin alone were incubated with HaCaT and HeLa cells. 
After 24 h of incubation at 37 °C, the cell viability was measured using either a tetrazolium- 
or resazurin-based cell viability assay, respectively (Figure 34).  
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Figure 34. Cytotoxic profile of peptides against human keratinocytes (A) and cancer cells (B). Cells were incubated 
with indicated concentrations of peptides at 37 °C for 24 h. Cell viability of HaCaT cells was determined by MTT assay whereas 
the toxic effects against HeLa cells were analyzed by a resazurin-based cell viability assay relative to untreated cells. As 
positive control, cells were treated with 70% EtOH for 10 min. Experiments were conducted in triplicate with n = 3. Error bars 
represent standard deviation. 
As seen in Figure 34A, no cytotoxic activity at all was detected when HaCaT cells were 
incubated with Tylotoin within concentrations of up to 100 µM. Moreover, Tylotoin seemed 
to enhance the proliferation of HaCaT cells, which agrees with previously reported data 
[126]. The same effect was observed when keratinocytes were treated with sC18* alone 
and Tylotoin-sC18*. But within the given concentration range, a slight decrease in cell 
viability was detected for sC18*-Tylotoin. The incubation with sC18 and sC18-Tylotoin 
caused cytotoxic effects at higher concentration (> 50 µM), whereas the cell viability was 
not affected when HaCaT cells were incubated with Tylotoin-sC18.  
Strikingly, the cell viability was much more negatively affected when cancer cells were 
treated with peptide conjugates for 24 h (Figure 34B). Interestingly, when compared to 
sC18* variants, chimeric peptide conjugates where sC18 is combined with Tylotoin caused 
a stronger decrease in cell viability in a concentration-dependent manner. As before, 
Tylotoin showed no relevant cytotoxic effects on the cells viability. Furthermore, the 
cytotoxic profile of sC18 and sC18* exhibiting no remarkable decrease in cell viability which 
agrees with former published results [68, 77, 130].  
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Even if the proliferative effect of HaCaT cells, as observed for Tylotoin, was less remarkable, 
the novel peptide conjugates provide a good template for additional studies to develop a 
new topical agent for wound healing, since the results clearly demonstrate no harmful 
effects on keratinocytes cell viability at lower concentrations. In contrast, the novel chimeric 
peptides revealed more distinct cytotoxic effects against the cancer cell line in a 
concentration-dependent manner, suggesting that these peptides might be exhibit in 
somehow selectivity towards cancer cells.  
These features make the novel peptide conjugates highly attractive for further experimental 
studies. 
4.2.3 Internalization into cells 
In a next step, the cellular internalization efficiency of the new peptide conjugates compared 
to their linear versions was elucidated when incubating them with HaCaT and HeLa cells, 
to gain some insights into the capability of peptides cell entry. 
Considering that the cytotoxic analysis revealed no harmful effects on cell viability, a non-
cytotoxic concentration of 10 µM was selected for the following internalization studies.  
First, both cell lines were incubated with 5(6)-carboxyfluorescein labeled sC18, the 
truncated version sC18* and Tylotoin alone. After 30 min of peptide incubation at 37 °C, the 
cells were treated with trypan blue solution to quench external fluorescence coming from 
surface-bound peptides and the cell nuclei were stained with the blue dye Hoechst 33342. 
The cellular uptake was then analyzed by confocal laser scanning microscopy (CLSM) and 
quantitatively by flow cytometry (Figure 35).  
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Figure 35. Cellular uptake of parent peptides into keratinocytes and cancer cells. Fluorescence microscopic images of 
human keratinocytes (A) and cancer cells (B) after 30 min incubation at 37 °C with 10 μM CF-labeled Tylotoin, sC18 and 
sC18*, respectively. External fluorescence was quenched by treatment with 150 µM trypan blue for 30 sec. Blue: Hoechst 
33342 nuclear dye, Green: 5(6)-carboxyfluorescein-labeled peptides. Scale bars, 10 µm. Flow cytometric uptake studies of 
10 µM CF-labeled peptides in HaCaT and HeLa cells at 37 °C for 30 min. Experiments were performed in triplicate with n = 
2. Error bars represent standard deviation (C). 
The fluorescence images of HaCaT cells treated with parent peptides are shown in Figure 
35A. Obviously, all peptides are capable to internalize into keratinocytes, moreover an 
accumulation into cytosolic vesicles was detected and a distribution within the nucleus 
which was more pronounced for the sC18 peptide. In cancer cells, the cellular uptake was 
slightly higher as further confirmed by flow cytometric analysis (Figure 35B and C). 
Especially, the accumulation of sC18 into the cell nucleus, and more specifically into the 
nucleoli, was distinctly stronger. However, Gronewold et al. have not shown such a strong 
internalization pattern for the cellular uptake of sC18 but this is might be attributed to 
different microscopic settings [68]. Interestingly, the uptake studies of the truncated version 
of sC18 showed an overall weaker uptake efficiency. This might be due to the missing 
positively charged amino acid within the sequence, since it was already reported that a 
minimum charge density is required to observe cellular internalization [125, 210].  
In this study, the uptake of Tylotoin into keratinocytes, moreover into the nucleoli, was 
reported for the first time. Nevertheless, for other amphibian skin peptides, e.g. Esc(1-21) 
[44] or temporin [43], internalization into the keratinocytes cytoplasm was already published. 
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Following, the cellular uptake of 10 µM and 1 µM CF-labeled chimeric Tylotoin conjugates 
within 30 min at 37 °C in HaCaT cells is shown in Figure 36.  
 
Figure 36. Internalization efficiency of Tylotoin peptide conjugates into HaCaT cells. Fluorescence microscopic images 
of human keratinocytes after 30 min incubation at 37 °C with 10 μM and 1 µM Tylotoin peptide conjugates (A), (B). External 
fluorescence was quenched by treatment with 150 µM trypan blue for 30 sec. Blue: Hoechst 33342 nuclear dye, Green: 5(6)-
carboxyfluorescein-labeled peptides. Scale bars, 10 µm. Flow cytometric uptake analysis of 10 µM and 1 µM CF-labeled 
Tylotoin conjugates in HaCaT cells at 37 °C for 30 min. Experiments were performed in triplicate with n = 3. Error bars 
represent standard deviation (C). 
After incubating the cells with 10 µM peptide solutions, keratinocytes showed cytosolic as 
well as vesicular distribution patterns. Moreover, at higher concentrations, a significant 
accumulation of all chimeric peptides in the cell nucleoli occurred. These observations were 
even more pronounced when CPP is fused to the N-terminus of Tylotoin. Decreasing the 
peptide concentration to 1 µM, the novel designed peptides almost failed to internalize 
which correlates well with the flow cytometric uptake studies (Figure 36C) at this 
concentration. From the observations at 1 µM peptide concentrations, one might conclude 
that theses peptides internalize by direct penetration, distributing throughout the cytosol and 
in the cell nuclei, and then accumulate in vesicular pattern. 
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Figure 37. Internalization efficiency of Tylotoin peptide conjugates into cancer cells. Fluorescence microscopic images 
of cancer cell line HeLa after 30 min incubation at 37 °C with 10 μM and 1 µM Tylotoin conjugates (A), (B). External 
fluorescence was quenched by treatment with 150 µM trypan blue for 30 sec. Blue: Hoechst 33342 nuclear dye, Green: 5(6)-
carboxyfluorescein-labeled peptides. Scale bars, 10 µm. Flow cytometric uptake analysis of 10 µM and 1 µM CF-labeled 
Tylotoin conjugates in Hela cells at 37 °C for 30 min. Experiments were performed in triplicate with n = 3. Error bars represent 
standard deviation (C). 
The cellular uptake efficiency of novel designed peptide conjugates in HeLa cells was then 
investigated, again with peptide concentrations of 10 and 1 µM (Figure 37). When compared 
with HaCaT cells, a much stronger vesicular accumulation was detected at both 
concentrations as seen in Figure 37A and B. Whereas, the cytosolic distribution as well as 
the accumulation within the cell nucleus seemed not as distinct. Nevertheless, the intrinsic 
fluorescence of peptide conjugates measured by flow cytometry revealed a significant 
greater uptake at higher concentrations and moreover, an overall remarkable higher uptake 
in cancer cells than in skin cells (with up to 10-fold higher uptake rates). Hence, these data 
might indicate that all peptide conjugates are localized in vesicular structures, possibly in 
endo- or lysosomes, which are then released into the cytosol and nucleus after an initial 
endo- and lysosome disruption.  
Taken together, the data obtained from HaCaT and HeLa cells, the uptake efficiency and 
the extent of the uptake pattern might be cell line-dependent, suggesting different affinities 
to uptake mechanisms which might be possible, since it has been reported that CPPs utilize 
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two or more pathways depending on the experimental conditions [69, 111]. But 
nevertheless, the combination of both peptides improved the cellular internalization towards 
the parent peptides and so far, no significant distinctions between the structural orientation 
of the peptides could be observed. 
To get a deeper insight into the cellular uptake pattern, the internalization of the novel 
designed peptides over a longer time frame was analyzed by fluorescence microscopy. 
Therefore, both cell lines were incubated with 10 µM CF-labeled peptides in the time interval 
of 30 and 120 min at 37 °C.  
The microscopic images of the cellular uptake of chimeric conjugates within 30 and 120 min 
into HaCaT cells are depicted in Figure 38. 
 
Figure 38. Time-dependent uptake of Tylotoin peptide conjugates into HaCaT cells. Fluorescence microscopic images 
of keratinocytes after incubation period of 30 min and 120 min at 37 °C with 10 μM sC18 variants (A) and sC18* variants (B). 
External fluorescence was quenched by treatment with 150 µM trypan blue for 30 sec. Blue: Hoechst 33342 nuclear dye, 
Green: 5(6)-carboxyfluorescein-labeled peptides. Scale bars, 10 µm.  
Besides cytosolic and nuclear peptide distribution, after an incubation time of 120 min, an 
additional punctuate pattern within the cells could be observed which was more obvious for 
Tylotoin-sC18 and Tylotoin-sC18*. However, the overall amount of internalized peptide 
variants seemed to stay equal over the evaluated time course.  
The time interval study of the novel designed peptides uptake into HeLa cells is depicted in 
Figure 39. 
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Figure 39. Time-dependent uptake of Tylotoin peptide conjugates into HeLa cells. Fluorescence microscopic images of 
cancer cells after incubation period of 30 min and 120 min at 37 °C with 10 μM sC18 variants (A) and sC18* variants (B). 
External fluorescence was quenched by treatment with 150 µM trypan blue for 30 sec. Blue: Hoechst 33342 nuclear dye, 
Green: 5(6)-carboxyfluorescein-labeled peptides. Scale bars, 10 µm.  
Here, it must be noted that the lower gain value used for the enhancement of the green 
signal (5.20 instead of 6.10, see Figure 37A and B) because otherwise, these images would 
have been overexposed. Nonetheless, after 120 min of peptide incubation, sC18 variants 
were stronger distributed within the cytoplasm and nucleus, more specifically into the 
nucleoli, which might be attributed to the slight decrease in cell viability at this peptide 
concentration. However, the amount of internalized sC18* variants during the time interval 
and the subcellular distribution seemed to remain more or less the same. 
So far, these data correlate well with the already mentioned observations. After a longer 
incubation period, the chimeric peptides were located within vesicular structures and 
concentrated mainly at the nuclear periphery. Moreover, the novel designed peptide 
conjugates could accumulate more efficiently in cancer cells as seen from flow cytometric 
analysis before. The preferential accumulation of peptides in cancer cells might be 
accompanied by slightly higher cytotoxicity towards cancer cells than to normal skin cells. 
Since all novel designed peptides showed no significant differences in uptake efficiency 
within a cell line (Figure 36C and Figure 37C) regardless whether the CPP is fused N- or C-
terminally to Tylotoin, it was referred to toxicity studies and structural characteristics to 
select the most suitable peptide conjugate. Owing to the proliferative effect observed in 
HaCaT cells and the non-cytotoxicity in HeLa cells at concentrations used for experiments, 
Tylotoin-sC18* was selected for further studies. Moreover, the helical wheel projection 
revealed two distinct phases when sC18* is combined to the C-terminus of Tylotoin resulting 
in a balanced ratio between hydrophilicity and hydrophobicity which is important for the 
initial step of cell entry [46, 77]. 
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Effect of endocytosis inhibition 
Hence, with this potent peptide conjugate in hand, the cellular uptake mechanism of 
Tylotoin-sC18* was further investigated in greater detail. It was examined whether the 
internalization of the chimeric peptide is dependent on endocytotic processes. Thus, the 
experimental set-up was conducted either at 4 °C to inhibit the energy-dependent pathway 
[102] or in the presence of dynasore, where the endocytosis is totally suppressed [141, 
176]. 
First, keratinocytes and cancer cells were incubated with 10 µM CF-labeled Tylotoin-sC18* 
for 30 min at 4 °C. The findings observed by fluorescence microscopy are presented in the 
upper panels of Figure 40A and B, respectively.  
 
Figure 40. Effect of endocytosis inhibition on cellular uptake of Tylotoin-sC18* in keratinocytes (A) and cancer cells 
(B). Cells were incubated with 10 µM CF-labeled Tylotoin-sC18* for 30 min at 4 °C (upper panel) or cells were pretreated with 
80 µM dynasore and subsequently with 10 µM CF-labeled peptide for 30 min at 37 °C. External fluorescence was quenched 
by treatment with 150 µM trypan blue for 30 sec. Green: 5(6)-carboxyfluorescein-labeled peptides, Blue: Hoechst 33342 
nuclear dye. Scale bars, 10 µm.  
The uptake of the peptide conjugate was slightly decreased in both cell lines relative to 
peptides incubation at 37 °C. However, the peptide is evenly distributed throughout the 
cytosol and in case of HeLa cells, the punctuate uptake pattern was not as strong as at 
37 °C. Moreover, Tylotoin-sC18* is still localized within the nucleoli, approving the 
assumption that the peptide, to a certain extent, is also able to enter the cells by direct 
penetration.  
Next, the cellular uptake studies were also performed in the presence of dynasore, a cell-
permeable dynamin inhibitor [110]. Therefore, both cell lines were preincubated with 80 µM 
dynasore for 1 h and subsequently CF-labeled Tylotoin-sC18* was added for another 
30 min at 37 °C. The microscopic images are depicted in the lower panels of Figure 40A 
and B, respectively. As expected, the internalization of chimeric peptide was not suppressed 
in dynasore-treated skin and cancer cells, respectively. Considering that dynasore prevents 
besides dynamin, which is essential for membrane fission during clathrin- and caveolin-
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mediated endocytosis, also the vesicle formation and fusion steps of macropinocytosis [141, 
176], it can be presumed that Tylotoin-sC18* is indeed capable to internalize by direct 
translocation.  
Intracellular destination  
Since the punctuate uptake pattern even when endocytosis is totally suppressed was still 
observed, yet another question of interest was to determine the intracellular fate of Tylotoin-
sC18* after the peptide incubation at 37 °C. 
Hence, after treating the cell lines with 10 µM CF-labeled Tylotoin-sC18* for either 30 or 
120 min, respectively, the peptide solutions were removed, extracellular fluorescence was 
quenched and cells were further incubated for 6 h in peptide-free medium. The microscopic 
images are shown in Figure 41. 
 
Figure 41. Intracellular fate of already internalized Tylotoin-sC18* after further 6 h of incubation in peptide-free media. 
Fluorescence images of HaCaT (A) and HeLa cells (B) treated with 10 µM CF-Tylotoin-sC18* at 37 °C for 30 and 120 min, 
respectively and after another 6 h of incubation in peptide-free medium. External fluorescence was quenched by treatment 
with 150 µM trypan blue for 30 sec. Green: 5(6)-carboxyfluorescein-labeled peptides, Blue: Hoechst 33342 nuclear dye. Scale 
bars, 10 µm. 
After incubating HaCaT cells with 10 µM peptide conjugate for 30 min and further incubation 
in peptide-free medium, a more obvious accumulation into cytosolic vesicles was observed. 
In contrast, the cellular uptake of Tylotoin-sC18* after 120 min and the intracellular fate after 
another 6 h of incubation showed similar distribution patterns within skin cells (Figure 41A). 
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As seen from Figure 41B, the amount of internalized Tylotoin-sC18* in HeLa cells and the 
localization within the cells remained more or less equal regardless of incubation time.  
Hence, these findings support the idea that in skin cells, the chimeric peptide conjugate is 
taken up by direct translocation after 30 min of incubation and over a longer time period, 
the peptides seemed to aggregate or might target specific cellular organelles since vesicular 
structures could still be observed. In HeLa cells, a punctuate uptake pattern was observed, 
which speaks in favor of an endocytotic uptake pathway, suggesting that the peptide is 
entrapped within endosomal vesicles and is not able to escape from endosomes. However, 
considering the only diminished cellular uptake at either 4 °C or in the presence of the 
endocytosis inhibitor and the fact that the peptide accumulated within the cell nucleoli, it is 
assumed that Tylotoin-sC18* is capable to enter the cells also by direct translocation.  
Subcellular localization 
Nowadays, specific organelle and tissue targeting is a major goal to ensure selective 
delivery of various therapeutic agents to reach its site of action within the cell [29, 158]. 
Thus, a large body of literature exists that demonstrates the successful application of CPPs 
to transport covalently or non-covalently linked therapeutic active biomolecules across the 
cell membrane and thus, enabling them to reach their specific cellular target [29, 68, 78, 
158].  
Owing to the fact that the peptides still accumulated within vesicular structures, it should be 
figured out whether Tylotoin-sC18* traffics specific intracellular organelles, like the 
endoplasmic reticulum (ER), lysosomes or mitochondria. Therefore, the localization of the 
peptide conjugate was investigated in the presence of specific cell organelle trackers.  
For this purpose, both keratinocytes and cancer cells were incubated together with 10 µM 
CF-labeled peptides and either 1 µM Mito-Tracker or 75 nM Lyso-Tracker for 120 min at 
37 °C, respectively. To verify the ability of Tylotoin-sC18* to target the ER, the red 
fluorescent dye ER-Tracker, which selectively localizes into endoplasmic reticula, was 
added 15 min prior to the end of peptide incubation. Then, microscopic analysis of possible 
co-localization was performed by confocal laser scanning microscopy. 
The fluorescence images shown in Figure 42 represent the organelle localization stained 
with red fluorescent dye, the peptide labeled with 5(6)-carboxyfluorescein (green) and in 
blue the nuclear marker. 
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Figure 42. Cell organelle targeting study of Tylotoin-sC18* within keratinocytes (A) and cancer cells (B). Fluorescence 
images of cells stained with1 µM ER-Tracker for 15 min, 75 nM Lyso-Tracker and Mito-Tracker were incubated together with 
10 µM CF-Tylotoin-sC18* for 120 min at 37 °C, respectively. External fluorescence was quenched by treatment with 150 µM 
trypan blue for 30 sec. Red: stained organelles, Green: 5(6)-carboxyfluorescein-labeled peptide, Blue: Hoechst 33342 nuclear 
dye, Scale bars, 10 µm. 
First, it should be noted that the staining of the organelles was successful and worked very 
well, as seen in the red channel in Figure 42A and B. Furthermore, when using the different 
stains, the CF-labeled peptide showed similar intracellular distribution and the morphology 
of the nuclei looked quite well corroborating that the organelle labeling did not affect the 
cellular uptake. 
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Moreover, one could hardly detect any co-localization at all, either in HaCaT or in Hela cells, 
since the merged pictures revealed no obvious overlay of the red and green signal coming 
from the organelle staining and the labeled chimeric peptide, respectively.  
Taking these observations into account, the novel designed peptide did not target the 
specific cellular organelles investigated. Consequently, the findings of this experiment 
support the hypothesis that the peptide aggregates over the time in keratinocytes and is, in 
case of the cancer cell line, still to some extent localized within vesicular structures. This 
leads to the assumption that the peptide might be entrapped within endosomes and has not 
yet been transported to lysosomes for degradation, since no co-localization with the Lyso-
Tracker was observed. In a recent study, Qian et al. provide another explanation, which 
supports the idea of peptide aggregation [143]. Thus, Qian and coworkers suggested a 
novel mechanism for cell-penetrating peptides and their endosomal release process. Using 
model membranes and mammalian cells, they proposed that CPPs bind directly to the 
endosomal membrane, inducing membrane curvature and thus leads to budding of small 
vesicles which finally collapse into peptide/lipid aggregates [143]. 
Therefore, it is possible that Tylotoin-sC18* might escaped from endosomes and reached 
the cytosol, apparently through budding and subsequent rupture of small vesicles.  
4.2.4 Peptide-lipid membrane interaction 
In a next level, it was further focused on the initial stage of peptides cell entry and thus, one 
took advantage of artificial model membranes, more precisely giant unilamellar vesicles 
(GUVs).  
Since Tylotoin-sC18* is rich in positively charged residues resulting in a net charge of +13 
at physiological pH and due to the fact that electrostatic interactions between positively 
charged CPPs and the negative charges within the cell membrane are of particular 
importance during the first stage of peptides cell entry [20, 85, 86], both zwitterionic and 
anionic lipid model systems were employed to ensure better comparability.  
Therefore, giant unilamellar vesicles either composed of zwitterionic lipids (DOPC and 
DOPE) or with additional incorporation of DOPG as negatively charged phospholipid were 
prepared and subsequently, the interaction and binding affinity of Tylotoin-sC18* towards 
both membrane compositions were investigated using confocal laser scanning microscopy.  
For that, 20 µM of CF-labeled Tylotoin-sC18* as well as CF-Tylotoin and CF-sC18* serving 
as controls were incubated with neutral GUVs (DOPC/DOPE, 50:50) (Figure 43A), and 
anionic GUVs (DOPC/DOPE/DOPG, 40:30:30) (Figure 43B) for 90 min. For visualization, 
GUV membranes were additionally doped with 0.2 mol% Atto550 labeled DOPE (red) and 
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to monitor the GUV membrane integrity, vesicles were loaded with the blue fluorophore 
Oyster 405. 
 
Figure 43. Interaction of Tylotoin-sC18* and its precursor peptides with model membranes. CF-labeled peptides 
(20 µM) were incubated with neutral (A) and negatively charged GUVs (B) loaded with Oyster 405 (blue dye) for 90 min and 
analyzed by CLSM. To visualize their membranes, vesicles were prior doped with 0.2 mol% Atto550-labeled DOPE (red). 
Scale bars, 30 µm. 
As shown in Figure 43A, no significant accumulation of peptides on membranes of neutral 
GUVs was observed, since no overlay with the red-labeled vesicle membrane could be 
detected. Furthermore, the influence of peptides on membrane integrity was examined by 
studying induced leakage of a GUV-encapsulated blue fluorescent dye. But again, no 
noticeable differences in the Oyster 405 signal (blue) before and after peptide addition could 
be revealed and thus, no obvious dye release. Owing to the fact that the presence of anionic 
lipids is crucial to trigger peptide-membrane interactions of cationic peptides [35, 181], these 
findings are in accordance with the literature.  
In contrast, when anionic GUVs were incubated with 20 µM of CF-labeled peptide solutions, 
a strong peptide signal on the membranes within 90 min could be detected, except for CF-
Tylotoin (Figure 43B). Here, no obvious membrane interaction could be observed at this 
concentration for Tylotoin alone. However, the strong membrane interaction observed for 
CF-sC18* and CF-Tylotoin-sC18* demonstrated the importance of negatively charged lipids 
to accumulate to these vesicle membranes. These results are in line with previous reports 
proving that the presence of negatively charged counter-anions, such as 
phosphatidylglycerol (DOPG) or pyrenebutyrate (PyB), is essential to induce the peptide-
membrane interactions of arginine-rich peptides [35, 91, 181]. Moreover, previous studies 
have demonstrated that the cellular membrane of cancer cells is primary anionic [85, 120], 
which is interesting considering that our novel peptide conjugate showed an overall stronger 
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accumulation on anionic GUV membranes compared to neutral ones, suggesting 
preferential accumulation towards cancer cells as already mentioned previously from 
internalization studies.  
Furthermore, the interaction of Tylotoin-sC18* with the anionic lipid membrane resulted in 
a significant dye release, indicating that the membrane becomes prone to leak as well as in 
peptide influx as seen from the green signal within the vesicle, presumably leading to pore 
forming events. This observation is in accordance with Cahill, K., who reported that the 
higher the number of positive charges, the higher is the propensity of the peptide to induce 
pore formation in membranes [25]. Moreover, the results observed for CF-labeled sC18* 
are in close agreement with those obtained by Horn et al. [77] as well. However, since the 
vesicles were still good in shape after the treatment with the peptide conjugate, the pore 
forming events are not accompanied by membrane disruption. Presumably, Tylotoin-sC18* 
is able to translocate the lipid bilayer quickly through transient pore-like structures. This 
assumption is similar to that reported by Herce et al., who revealed by molecular-dynamics 
simulations that the Arg-rich Tat peptide crosses phospholipid bilayers by destabilizing the 
membrane and inducing transient pores, which close after a few peptides translocate [75]. 
A further possible explanation for the dye release and the peptide influx without destroying 
the vesicle membranes may involve the mechanism of loosening lipid packing, which might 
enhance the hydrophobic interaction of the peptide backbone with lipid acyl chains, thus 
facilitating the membrane translocation of Arg-rich peptides. A recent study by Murayama 
et al. supports this interpretation [127]. They reported on the formation of so called lipid 
packing defects, caused by membrane bending [190], as key factor that governs the 
translocation of Arg-rich CPPs across the membrane (Figure 44) [127]. 
 
Figure 44. Direct translocation of R8 through the lipid bilayer. This process is facilitated by curvature-induced defects in 
lipid packing (A). These defects in lipid packing arise from membrane bending caused by the interaction of guanidium functions 
and the phosphate groups of membrane lipids (B). (modified after Mishra et al., 2011 [123] and Murayama et al., 2017 [127]) 
Thereby, the formation of bidentate hydrogen bonds between the guanidium moieties of Arg 
and the phosphate groups of membrane lipids induces positive membrane curvature (Figure 
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44B), which resulted in membrane structural defects, enabling the direct translocation of 
oligo-arginine (R8) across the plasma membrane (Figure 44A) [127]. 
Moreover, since model membrane systems are not affected by endocytotic processes, 
these findings further support the hypothesis that Tylotoin-sC18* is indeed able to directly 
penetrate the cell membrane through membrane destabilization effects.  
4.2.5 Efficacy of Tylotoin-sC18* on keratinocyte migration in a scratch-
wound closure assay 
Keratinocytes are the predominant cell type of the epidermis, the outermost layer of skin, 
and thus provide a physical barrier between the organism and the environment, protecting 
it from external agents and pathogens [136]. Upon injury of the skin, as the epidermal barrier 
is disrupted, migration and proliferation of keratinocytes represent a crucial step in the re-
epithelization phase of the wound healing process [119, 136, 166, 201, 208].  
Here, the ability of Tylotoin-sC18* to induce migration and proliferation of keratinocytes into 
a wound area was investigated using an in vitro wound closure assay. Therefore, confluent 
monolayers of HaCaT cells cultured in 12-well plates were mechanically scratched with a 
sterile pipette tip and then allowed to re-epithelialize for 30 h at 37 °C in the presence of 
Tylotoin-sC18*. 
Since Mu et al. demonstrated that Tylotoin promotes migration of HaCaT cells in a 
concentration-dependent manner [126], the concentration of 13.5 µM for the peptide 
conjugate was selected. Furthermore, the human epidermal growth factor (hEGF) was used 
as positive control and untreated cells served as negative control. The cell migration was 
monitored by phase-contrast microscopy depicted in Figure 45. 
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Figure 45. Tylotoin-sC18* promotes migration of HaCaT cells. Confluent cells were wounded by scratching with a pipette 
tip and then treated with 13.5 µM Tylotoin-sC18*, 13.5 µM Tylotoin and 100 ng/ml hEGF, respectively. Cells incubated with 
maintenance medium only served as control. Wound closure was monitored at 0, 7, 25 and 30 h after peptide addition by 
inverted light microscope (A). The percentage of corresponding cell-covered area at each time point (B) and the average 
speed (% wound closure/hours) (C) were analyzed by Wimasis Image Analysis.  
In Figure 45A, compared to migration in the untreated control group, the migration of 
keratinocytes into the wounded area was distinctly increased in the presence of Tylotoin-
sC18* 30 h after scratching, similar with the human epidermal growth factor (hEGF). 
Moreover, the ability of Tylotoin-sC18* to enhance migration of keratinocytes seems to be 
improved compared to Tylotoin alone, since the average speed of the cell-covered area per 
hour was accelerated for Tylotoin-sC18* (Figure 45C). These findings indicated that the 
novel designed peptide conjugate had comparable migration efficiency with Tylotoin and 
hEGF, suggesting that the CPP connected to Tylotoin did not cause any loss in its activity. 
Moreover, the combination of both peptides might further improve the wound healing 
promoting ability of Tylotoin. 
However, since wound closure results from both cell migration and proliferation, the wound 
healing assay was also performed in the presence of mitomycin C, which is known to inhibit 
mitosis of the cells and thus allows to distinguish migration from proliferation [45, 95].  
Therefore, confluent monolayers of keratinocytes were preincubated with 20 µM mitomycin 
C for 90 min to prevent cell proliferation. Subsequently, the migratory effect of Tylotoin-
sC18* compared with untreated cells was monitored in the wound healing assay depicted 
in Figure 46. 
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Figure 46. Influence of mitomycin C on Tylotoin-sC18*-induced wound closure. Confluent monolayer of immortalized 
HaCaT cells were treated with 20 µM mitomycin C for 90 min prior to scrape formation to avoid cell proliferation. Wound 
closure in the presence of 13.5 µM peptide or even maintenance medium was monitored after 0, 7, 25 and 30 h by inverted 
light microscope, respectively (A). The corresponding mean speed (% wound closure/hours) of wound healing was calculated 
by Wimasis Image Analysis (B).  
Data shown in Figure 46A conclude that the wound healing rate of Tylotoin-sC18* is higher 
than in the control group, since a larger number of cells migrated into the wounded gap in 
the presence of chimeric conjugate, which resulted in complete wound closure. But taking 
a closer look on average speed, expressed as cell-covered area per hour, it was found that 
the presence of mitomycin C remarkably suppresses the cell migration ability of Tylotoin-
sC18* (Figure 46B).  
These results might illustrate that besides migration also proliferation of HaCaT cells 
contributes to the wound healing effect induced by Tylotoin-sC18* as well. 
4.2.6 Mechanism of peptide-induced cell migration 
As several cytokines and growth factors have been shown to influence the process of re-
epithelialization [27, 119], the epidermal growth factor receptor (EGFR) was selected to 
further investigate the pathway by which Tylotoin-sC18* induces migration and proliferation 
of keratinocytes. So far, authors of several studies have demonstrated the importance of 
human EGFR to enhance both keratinocytes migration and proliferation [9, 31, 34, 131]. 
Moreover, it was already shown for e.g. LL-37 [182], Esculentin-1a(1-21) [44], a derivative 
of a frog skin AMP, and DRGN-1 [34], an AMP obtained from plasma of Komodo dragon, 
to act in a EGF-receptor dependent manner. 
Thus, to examine whether Tylotoin-sC18* is also capable to activate the EGFR pathway, 
the potential phosphorylation of the EGF-receptor was analyzed by Western blotting using 
an anti-phospho EGFR antibody.  
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Since Tokumaru et al. revealed that LL-37 phosphorylated EGFR within 10 min enduring 
for 15 min [182], subconfluent HaCaT cells were stimulated with 13.5 µM Tylotoin-sC18* for 
three indicated time points, 5, 15 and 25 min, respectively. The human epidermal growth 
factor served as positive control and the EGFR inhibitor tyrphostin AG1478 was added 
10 min prior to EGF treatment to confirm the contribution of EGFR signaling in EGF induced 
migration of keratinocytes.  
 
Figure 47. Effects of Tylotoin-sC18* on EGFR activation in HaCaT cells. Subconfluent keratinocytes were starved in 
serum-free medium for 16 h and subsequently stimulated with 13.5 µM Tylotoin-sC18*. The cells were harvested into lysis 
buffer at the indicated time points. hEGF (100 ng/ml) served as positive control. For EGFR inhibition, cells were pretreated 
with 0.2 µM AG1478 for 10 min and subsequently treated with hEGF for 5 min. EGFR indicates total EGFR protein. 
As illustrated in Figure 47, EGF treatment led to phosphorylation of the EGF-receptor at 
5 min. Moreover, the activation of EGFR was significantly impaired by inhibiting EGFR-
mediated signaling through AG1478, confirming the importance of EGF during the process 
of re-epithelization. However, no activation of EGFR was observed at all when keratinocytes 
were stimulated with Tylotoin-sC18*, indicating that the peptide-induced migration and 
proliferation of keratinocytes does not occur via EGF/EGFR signaling pathway.  
4.2.7 Antimicrobial activity 
Since the complex process of wound healing is often affected by bacterial infections, which 
is also a key reason why wound repair may decelerate, and thus leading to increased risks 
of patient morbidity and mortality, there is an urgent need to discover new treatments for 
microbial infected wounds [93, 101]. Furthermore, due to the currently increasing number 
of multidrug-resistant bacteria, other antimicrobial agents like AMPs may provide an 
attractive alternative to conventional antibiotics [116].  
Recently, it was shown by our group that the cell-penetrating peptide sC18 revealed still 
moderate antimicrobial activities, which could be further increased by conjugation with 
imidazolium salts [148] as well as the exchange of specific amino acids with phenylalanine 
leading to enhanced antimicrobial activities [150]. Furthermore, Mu and coworkers have 
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highlighted the important role of the antimicrobial peptide Tylotoin during wound healing 
events, as mentioned earlier [126]. Moreover, there is even more evidence for AMPs to be 
important modulators in wound healing often accompanied by multiple beneficial features 
e.g. antimicrobial activities against a broad spectrum of bacteria or the positive effects on 
cellular behaviors during wound repair [61, 116]. 
Therefore, it was particularly interesting whether the combination of both, Tylotoin and 
sC18*, would lead to an efficient peptide conjugate with antimicrobial activity.  
Hence, the antimicrobial effect of Tylotoin-sC18* as well as Tylotoin and sC18* alone was 
tested within a concentration range of 2.5 to 25 µM against M. luteus as representative for 
gram-positive bacteria and S. typhimurium as representative of gram-negative bacteria 
using INT-assay.  
 
Figure 48. Antimicrobial effect of peptides against gram-positive and gram-negative bacteria. M. luteus and 
S. typhimurium were incubated with indicated concentrations of peptides at 37 °C. After 6 h of incubation, bacterial survival is 
expressed as percentage with respect to water-treated bacteria using INT assay. Treatment with 70% EtOH served as positive 
control. Experiments were achieved in triplicate with n = 2. Error bars represent standard deviation. 
As illustrated in Figure 48, the parent peptides Tylotoin and sC18* revealed no toxic effect 
against the gram-positive bacteria within the defined concentration range. Moreover, due to 
conditions of stress caused through peptides, the growth of M. luteus was slightly increased. 
However, the novel peptide conjugate revealed the strongest activity against the gram-
positive bacteria, thus relative bacterial survival was diminished by about 20% at 10 µM and 
decreased further to 30% of living bacteria at a peptide concentration of 25 µM. Similar 
results were obtained when gram-negative bacteria were incubated with peptides for 6 h as 
depicted in the right panel of Figure 48. Here again, Tylotoin-sC18* revealed antimicrobial 
effects at higher concentration against S. typhimurium, while Tylotoin and sC18* alone 
showed no antimicrobial activities.  
Consequently, since parent peptides do not show any toxic effects at all, it can be assumed 
that the combination of both peptides leads to an efficient peptide conjugate with indeed 
significant antimicrobial activity in a concentration-dependent manner against both gram-
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positive and gram-negative bacteria. Moreover, considering that anionic phospholipid 
headgroups are not only related to cancer cells but also a main constituent of bacteria lipid 
bilayer [135, 184], these findings provide further support for the hypothesis that peptides 
with positively charged amino acids accompanied by an amphipathic character are essential 
for the initial step of cell entry as well as for the interaction with bacterial membranes.  
Finally, owing to multiple features obtained for Tylotoin-sC18*, including antimicrobial as 
well as wound healing activities, this novel designed peptide conjugate Tylotoin-sC18* may 
represent a promising agent for new therapeutic approaches in the treatment of infected 
wounds.  
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5. Conclusion and outlook 
CPPs and the interaction with membrane components 
Over the recent decade, cell-penetrating peptides have gained extensive interest due to 
their capability to penetrate the cell membrane and even more to deliver a wide range of 
various bioactive molecules inside the cells, which would otherwise be unable to cross the 
membrane barrier because of their size and hydrophilic nature [71, 84]. Thus, CPPs have 
emerged as very promising delivery vehicles in the field of therapeutic agents [16, 84].  
So far, a large body of literature exists that reported on the development and modification 
of new CPPs to further improve their internalization efficacy, specificity and the cellular 
delivery of therapeutic agents [55, 207]. Despite that, the cellular mechanism behind is still 
a subject under debate and has to be urgently resolved [111]. For this purpose, great efforts 
have been put into the clarification of peptides mode of action. Thereby, the employment of 
artificial membrane systems has lately gained widespread popularity to comprehend the 
molecular requirements and mechanism of cell entry. 
In this thesis, different biophysical techniques, which are accompanied by the use of model 
membrane systems, were successfully established with the final goal to gather important 
and useful information about cell-penetrating peptides initial step of cell entry. Thus, one 
focus laid on assessing the interaction between two variants of structural modified CPPs 
and different lipid membrane systems. Recently, we reported on structural modifications of 
the cationic CPP sC18 with the aim to enhance its efficiency as cell-penetrating peptide [68, 
77, 78]. More precisely, on the one hand, the peptide backbone of the shortened variant of 
sC18 was cyclized resulting in cyclic structures varying in size and on the other hand, a 
branched dimeric version of sC18 and sC18* was employed.  
Herein, by using large and giant unilamellar vesicles, the essential role of negatively 
charged lipids for cationic cell-penetrating peptides in cellular translocation was underlined, 
despite whether the peptides were branched or cyclic. Thus, as a first step, binding of the 
CPPs to anionic lipids would occur mainly by electrostatic interactions through the 
hydrophilic nature of the CPPs. 
In case of dimeric peptide variants, the enhanced interaction with the anionic model 
membranes, mimicking cancer cells, was further accompanied by stronger membrane 
perturbation effects compared to monomeric control peptides. These observations were 
confirmed by the peptide-induced dye release experiments. In this set-up, a rapid and 
efficient CF release in a matter of a few minutes was detected, and might indicate pore 
forming events. Overall, the preferential accumulation with anionic lipids and the 
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membrane-active properties might be related to the high charge density of the dimeric 
peptides over their monomeric versions.  
From this point, it is quite interesting that several studies reported on the enhanced anionic 
nature of cancer cell membranes [85, 86] when considering the stated selectivity of (sC18)2 
towards tumor cells [68, 78]. Consequently, the enhanced interactions with negatively 
charged membranes might be contributed to its effectiveness as a lytic anticancer peptide.  
Moreover, cholesterol was turned out to play an important role in initial membrane binding 
and peptides membrane disrupting activity in large unilamellar vesicles mimicking lipid-raft 
domains. Abolishing the formation of liquid-ordered domains by cholesterol extraction using 
MβCD resulted in significantly diminished uptake efficiency of (sC18)2 as observed for 
HEK- 293 and MCF-7 cells as representatives of healthy and cancer cells, respectively. In 
agreement with the literature, several publications underlined that cholesterol extraction led 
to a remarkable diminution in the internalization efficiency of the well-characterized Tat 
peptide [90] and penetratin [105], a result which was assumed to be related to the inhibition 
of raft-dependent endocytosis of these peptides [175]. Thus, it might indeed be possible 
that (sC18)2 penetrates the cells, besides direct translocation, via raft-dependent 
endocytosis, since a crucial role in endocytosis is attributed to cholesterol [80].  
However, judging from the aspect that one of the unresolved subjects in the application field 
of CPPs in therapeutics relates to the lack of selectivity towards targeted cells or intracellular 
compartments [85], these results might provide initial insights of molecular requirements 
important to improve their in vivo efficiency and target-specificity.  
Focusing on cyclic peptide variants, the high content of negatively charged phospholipids 
within vesicle membranes has also increased their binding affinity as observed from 
microscopic and flow cytometric analysis. Together with previously mentioned 
observations, this further supports the idea that electrostatic interaction is indeed 
responsible for the initial binding of sC18 conjugates to plasma membranes. 
Furthermore, the structural arrangement of peptides seems to play a role as well in peptide-
membrane interactions [130, 171]. Thus, CD spectroscopy revealed that of course the small 
cycle cyc1 and its linear counterpart attained a transition to an α-helical formation when in 
contact with negatively charged LUVs. Despite the strong binding affinity of cyc3 to anionic 
lipids, no obvious secondary structure conformation could be obtained. These findings were 
additionally corroborated by solution phase NMR studies shown by Horn et al. [77]. Here, 
the structures of the linear peptide sC18* and the large-sized cycle cyc3 were examined in 
the presence of SDS micelles as a membrane-mimetic environment. The NMR 
spectroscopy of the linear counterpart revealed a short helical fragment between the 
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residues R3 - R7 at the N-terminus. On the contrary, cyc3 did not show any secondary 
structural motif even if the final structure is not completely unordered [77].  
However, the ability of cyc3 to interact with both neutral and anionic LUVs might be 
attributed to the flexibility of the larger ring size enabling cyc3 to adopt the most suitable 
structure required for efficient interaction with the membrane bilayer. Therefore, a certain 
flexibility and thus the static arrangement of the guanidinium groups within the large cycle 
seems to positively affect peptide-membrane interaction, thus leading to cellular uptake. 
Additionally, for these cyclic peptides, it was aimed to elucidate in more detail how cells 
plasma membrane compounds affect peptides cell entry in conditions lacking endocytosis. 
Herein, the findings suggest that some membrane proteins embedded within the vesicle 
membrane could specifically increase the peptide uptake across the cell membrane. 
However, further investigation is required. 
Finally, the present data let one assume that the lipid composition of the target membrane 
plays a critical role in the initial stage of cell contact and thus peptides mode of action. The 
modified peptide variants of sC18 demonstrated improved binding and membrane activities 
over their linear counterpart sC18 and sC18*.  
Beyond that, this study demonstrates the usefulness of plasma membrane vesicles as 
membrane models in biophysical studies of investigating peptide-membrane interactions in 
order to provide new and detailed molecular understanding of how CPPs interact with the 
cellular membrane of eukaryotic cells. Even though, these results cannot be directly 
translated into peptides mode of action, it can provide a good starting point to develop 
peptides with improved uptake efficiencies and moreover with specific cell or tissue 
selectivity. 
Nevertheless, the next step would be to analyze the exact lipid composition of the plasma 
membrane of the cell lines used, since it has been assumed that the uptake mechanism of 
our peptide conjugates is dependent of a certain membrane composition and microdomain 
organization. This could be achieved by plasma membrane isolation of HEK-293 and 
MCF- 7 cells using sucrose density centrifugation accompanied by lipid detection via mass 
spectroscopy [195, 202]. Using this method, Wallbrecher et al. demonstrated lately that the 
plasma membrane of HEK-293 contains only minor amounts of sphingomyelin compared 
to HeLa cells. This probably resulted in a more resistant membrane for HeLa cells, a result 
interpreted as reason why nona-arginine (R9) entered HEK cells by direct penetration 
already at low concentrations [195]. 
Finally, once taken up into cells, the CPPs might interact and translocate across 
membranes of different compositions when entering or escaping the different intracellular 
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organelles. Therefore, the knowledge about lipids present in the membranes should be 
increased in order to understand the peptide-lipid relationship.  
CPPs and wound repair 
Wound repair is an evolutionarily conserved process among species [12, 178]. However, 
this complex process differs between mammalians and amphibians. Hence, lower 
vertebrates, e.g. axolotl or Xenopus are capable of scarless wound healing and to 
regenerate fully functional limbs [108, 205] in an incredible quick time when compared to 
wound healing in mammalians [126] making this field highly attractive to study. 
Recently, Mu et al. highlighted Tylotoin, a short peptide identified from salamander skin, as 
a potent template for the development of novel wound healing agents due to its efficient 
wound healing abilities [126]. In this thesis, a wound healing promoting peptide and a cell-
penetrating peptide were combined for the first time with the ultimate goal to improve the 
delivery of Tylotoin across the cell membrane. Moreover, the ability of sC18* to further 
improve the migration of keratinocytes was evaluated. Since keratinocytes are key cellular 
components of the epidermis, which are involved in wound healing, the investigation could 
further shed light on a potential wound healing efficacy.  
The structural analysis using circular dichroism spectroscopy revealed that the presence of 
sC18 supported the transition to an α-helical conformation for the chimeric peptides in a 
membrane-mimetic environment. Moreover, the fusion of the CPP to the C-terminal part of 
Tylotoin leads to a better hydrophobic/hydrophilic balance allowing optimal interaction of 
the peptide conjugates with the amphiphilic nature of biological membranes.  
Nevertheless, so far, nothing is known about the translocation mechanism of Tylotoin into 
mammalian cells. Therefore, the uptake of N-terminally 5(6)-carboxyfluorescein labeled 
peptide conjugates into skin cells and HeLa cells, as representative for cancer cells, was 
studied by confocal laser scanning microscopy and flow cytometry. The chimeric peptides 
were found to exhibit improved cellular internalization efficiencies compared to the parent 
peptides. In addition, the observed vesicular structures within the cytosol speak in favor for 
an uptake mechanism via endocytosis. However, in the presence of dynasore, an 
endocytosis inhibitor, and at lower temperature, the cellular uptake was diminished but to 
our surprise, the chimeric peptide Tylotoin-sC18* was still localized within the cytosol in 
punctuate pattern and moreover in the nucleoli leading to the assumption that the conjugate 
can penetrate the cells also via direct translocation.  
Though, since these vesicular structures were still observed even when endocytosis is 
totally suppressed and the peptide signal did not match with any organelle tracker used, 
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these findings might arise the hypothesis that the peptides get intracellularly aggregated 
over time. 
Form this point, it will be interesting to investigate the internalization pathway in more detail. 
One concept could be to model the endosomal escape using giant unilamellar vesicles [112, 
143], since Qian et al. postulated a new mechanism of CPP uptake, shown in the following 
figure.  
 
Figure 49. A novel mechanistic model for the endosomal escape process. (adapted from Qian et al., 2016 [143]) 
This novel proposed mechanism based on the idea that the CPPs were taken up via 
endocytosis, CPPs subsequently bind to the lumen of the endosomal membrane, which 
finally leads to vesicle budding and/or peptide/lipid aggregates [143]. Therefore, giant 
unilamellar vesicles could be prepared mimicking the lipid composition of early and late 
endosomes to study the effect of different pH values e.g. to mimic the acidic environment 
in late endosome and thus the mode of action. Furthermore, it will be interesting to generate 
model membrane systems encapsulating the peptide in the lumen due to the fact that during 
endocytosis, peptides are trapped inside the endosomes. 
Beyond that, it could be shown that the fusion of the cell-penetrating peptide to Tylotoin did 
not result in a loss of Tylotoins activity, on the contrary, Tylotoin-sC18* might further improve 
the wound healing promoting ability of Tylotoin as illustrated by the activity to promote in 
vitro wound closure by inducing migration and proliferation of keratinocytes. A next step 
would be the delivery of Tylotoin-sC18* across the skin. Besides in vitro cell culture models, 
several models for wound repair exist including in vivo human and animal skin models as 
well as ex vivo models, e.g. full-thickness skin models [1, 54, 164]. Since animal models, in 
particular rodents, do not accurately represent the structure of the human skin and owing 
to ethical and moral issues, the need for alternative skin models is essential [1, 187]. The 
use of artificial and reconstructed human skin equivalents is therefore receiving more 
attention [54]. Artificial in vitro skin models range from simple homogenous polymer 
materials, e.g. silicone membranes through to lipid-based models [1, 54]. Whereas 
reconstructed skin models are cell culture-based models containing layers of human cells 
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in culture laid down over a polymeric matrix [54]. Although in vitro models are sufficient to 
identify the key underlying mechanisms and to aim a better understanding of the process 
of wound repair, in vivo experiments are indispensable for effective drug development [11].  
Concerning the molecular mechanism behind, several studies reported on the involvement 
of the epidermal growth factor receptor (EGFR) in the peptide-induced signaling pathway 
controlling keratinocytes migration [44, 138, 182]. However, Tylotoin-sC18* does not induce 
cell migration via the EGF/EGFR signaling pathway. Besides the epidermal growth factor, 
numerous other growth factors as well as cytokines participate in the wound healing 
process, e.g. transforming growth factors (TGF-βs), fibroblast and vascular endothelial 
growth factors, as well as several proinflammatory cytokines [19]. Since Mu et al. could 
already show that Tylotoin is able to induce TGF-β1 secretion in vitro and in vivo models, it 
should be interesting whether the conjugate Tylotoin-sC18* stimulates the release of TGF-
β1 and transactivates components of downstream TGF-β signaling, such as Smad2 and 
Smad2, as well [126]. Also, the MAPK (mitogen-activated protein kinase) pathway is likely 
involved in the regulation of keratinocytes migration [12]. Therefore, several approaches 
could be further investigated with the final attempt to identify the molecular mechanism.  
Nonetheless, Tylotoin-sC18* exhibited improved antimicrobial activity against 
representatives of gram-positive and -negative bacteria which is quite impressive since 
efficient wound healing is often hampered by bacterial infections [124]. Furthermore, the 
cellular uptake into the cancer cell line was much higher compared to skin cells, which might 
be contributed to the slightly higher toxicity of chimeric peptides against HeLa cells. 
Therefore, further studies will have to show whether these novel peptide conjugates may 
exhibit a certain selectivity towards cancer cells. 
Finally, with this potent conjugate in hand showing antimicrobial and wound healing 
promoting activities and moreover being non-toxic towards keratinocytes, a novel promising 
agent might be identified for new therapeutic approaches in the treatment of infected 
wounds.  
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7. Attachment 
7.1 List of abbreviations  
ACN   acetonitrile  
AMPs   antimicrobial peptides 
CD   circular dichroism 
CF   5(6)-carboxyfluorescein 
CH2Cl2   dichloromethane 
CHCl3   chloroform 
Chol   cholesterol 
CLSM   confocal laser scanning microscopy 
CPP   cell-penetrating peptide 
cyc   cyclic 
DIC   N,N-diisopropylcarbodiimide 
DiI   1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate  
DIPEA   N,N-diisopropylethylamine 
DMEM   Dulbecco’s Modified Eagle Medium 
DMF   N,N-dimethylformamide 
DOPC   1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE   1,2-dioleoyl-sn-glycero-3-phophoethanolamine 
DOPG   1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] 
DOPS   1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
DOTA   1,4,7,10-tetraazacyclotetradecane-1,4,7,10 tetraacetic acid 
DTT   dithiothreitol 
EDT   1,2-ethanedithiol 
EGF   epidermal growth factor 
eq.   equivalent 
ER   endoplasmic reticulum 
ESI-MS  electrospray ionization mass spectrometry 
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Et2O   diethyl ether 
EtOH   ethanol 
FA   formic acid 
FBS   fetal bovine serum 
Fmoc   9-fluorenylmethyloxycarbonyl 
GPMVs  giant plasma membrane vesicles 
GUVs    giant unilamellar vesicles 
HaCaT   Human adult low Calcium high Temperature keratinocytes 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HEK-293  human embryonic kidney 293 cell line 
HeLa   human cervical carcinoma cell line 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
Hoechst  bisBenzimide H 33342 trihydrochloride 
HPLC   high performance liquid chromatography 
INT   p-iodonitrotetrazolium-chloride 
KCN   potassium cyanide 
Ld   liquid-disordered phase 
Lo   liquid-ordered phase 
LUVs   large unilamellar vesicles 
M. luteus  Micrococcus luteus 
m/z   mass-to-charge ratio 
MCF-7   human breast adenocarcinoma cell line 
MeOH   methanol  
MTT   3-(4,5-dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide 
MW   molecular weight 
NEM   N-ethylmaleimide 
NIA   2-(2-nitroimidazol-1-yl)acetic acid 
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NODAGA 4‐(4,7‐bis(2‐tert‐butoxy‐2‐oxoethyl)‐1,4,7‐triazonan‐1‐yl)‐5‐tert‐
butoxy‐5‐oxopentaoic acid 
P/L   peptide/lipid ratio 
PFA   paraformaldehyde 
PI   phosphatidylinositol  
PI(4,5)P2  phosphatidylinositol-(4,5)-bisphosphate 
PMSF   phenylmethylsulfonyl fluoride 
PyB   pyrenebutyrate 
RPMI 1640  Roswell Park Memorial Institute, cell culture medium 
RT   room temperature 
S. typhimurium Salmonella typhimurium 
SC   Stratum corneum 
SDS   sodium dodecyl sulfate 
SM   sphingomyelin  
SPPS   solid phase peptide synthesis 
t-Bu   tert. butyl 
t-BuOH  tert. butyl alcohol 
TFA   trifluoroacetic acid 
TFE   trifluoroethanol 
TGF-β   transforming growth factor 
TIS/TIPS  triisopropylsilane 
v/v   volume per volume 
w/v   weight per volume 
 
amino acids: 
A   Ala   alanine 
B  Pra  L-propargylglycine 
C  Cys  cysteine 
E   Glu   glutamic acid 
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F   Phe   phenylalanine 
G   Gly  glycine 
I   Ile   isoleucine 
K   Lys  lysine 
L   Leu   leucine 
N   Asn   asparagine 
Q   Gln   glutamine 
R   Arg   arginine 
V   Val   valine 
X    L-(Ɛ-azido)-lysine 
Y  Tyr  tyrosine 
βA  βAla  β-alanine 
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